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In this review many examples are given of the complexities involved in using some biomarkers in
relation to assessing the effects of dietary exposure, when there is frequently a need to determine
changes following long-term low level exposure to dietary components. These range from under-
standing why the biomarker might be valuable and how best it can be measured, to the pitfalls
which can occur in the interpretation of data.
Analytical technique is considered in relation to folate and selenium, and flavonoid and caro-
tenoid species are used to illustrate how the metabolism of a compound may alter the validity or
adequacy of a marker. Vitamin A is discussed in relation to the difficulties which can arise when
there are several biomarkers that may be available to assess exposure to one nutrient. Vitamin B12
is discussed in relation to the dietary choices made by individuals. Possible interactions and the
role of measuring total antioxidant capacity is considered in some detail. In contrast to most
nutrients, there is a marked lack of biomarkers of either exposure or effect for most non-nutrients.
The role of biological effect monitoring is considered for dietary contaminants, fumonisins and
polyhalogenated aromatic hydrocarbons. Aflatoxins are discussed to exemplify food contami-
nants for which the biomarker approach has been extensively studied. Finally some compounds
which are deliberately added to foods and some which appear as processing contaminants are
each considered briefly in relation to the requirement for a biomarker of exposure to be
developed.
Biomarkers of exposure: Dietary intake: Nutrients: Non-nutrients
1. Introduction
This review is an assessment of the use of some biomarker
approaches used for assessing dietary exposure and intake.
Because many of the authors have analytical experience of
the examples given, the review assesses some of the
measurement techniques as well as the clinical appropriate-
ness of the biomarkers chosen. It is not intended to be an
exhaustive list of compounds or methods, but it is intended
to offer an ‘insight’ into the current state of the art with
regard to biomarkers of dietary exposure and effect.
2. Factors influencing the use of biomarkers of exposure
and effect for nutrients and non-nutrients
Ideally, biomarkers should be specific, sensitive and not
too invasive for human studies. These criteria are not
always met and the authors decided to focus their review
around the factors that might influence the use of a bio-
marker approach. Thus the effects of the analytical tech-
nique are considered in relation to folate and selenium.
How appropriate or robust are the methods in current
use? Biomarkers for flavonoid and carotenoid species
are used to illustrate how the metabolism of a compound
may alter the validity or adequacy of that marker. How
consistent are the several biomarkers that may be avail-
able to assess exposure to a vitamin for example? Vita-
min A is used to discuss this aspect whereas vitamin B12
is discussed in relation to the dietary choices made by
individuals. The role of biological effect monitoring is
considered for dietary contaminants, fumonisins and
polyhalogenated aromatic hydrocarbons.
One of the reasons that specificity for a biomarker
may be a problem is the number of possible interactions
which may occur within the human body. This aspect
and the role of measuring total antioxidant capacity is
considered in some detail. In the final two sections, bio-
markers for aflatoxins are used as an illustration of a
food contaminant for which the biomarker approach has
been extensively studied and the last section attempts to
highlight some of the areas in which there is a significant
lack of knowledge.
3. Effects of the analytical method
The analytical method used to determine a chosen bio-
marker may compromise the interpretation of the link
between dietary exposure and the biomarker. A good
example is the measurement of folate absorption and
metabolism.
3.1. Folate
3.1.1. Absorption and metabolism. Dietary folates exist
predominantly in a polyglutamated conjugated form.
Since the folate carrier transports the monoglutamate form
of the cofactor into cells, the folate polyglutamates must be
hydrolysed to the monoglutamate form by the enzyme folyl-
polyglutamate hydrolase, also known as conjugase. After
cell entry polyglutamylation occurs catalysed by the
enzyme folylpolyglutamate synthetase. Under normal
physiological conditions folates exist predominantly as
the penta- and hexaglutamates. Once inside the cell, folates
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can undergo interconversion into the various cofactor
forms along with both reduction and oxidation. In general,
studies on the distribution of the cofactor forms have
shown that tetrahydrofolate, 10-formyltetrahydrofolate,
and 5-methyltetrahydrofolate are the cofactor forms pre-
sent in the highest quantities in tissues and cells. Circulat-
ing folates are monoglutamyl derivatives mostly in the
form of 5-methyl tetrahydropteroylglutamate. Polygluta-
mate folates within the cell are incapable of cellular exit
unless they are converted back into monoglutamyl deriva-
tives. It is not possible at this time to predict the bioavail-
ability of folate for a given diet. The relative bioavailability
of synthetic polyglutamyl folates in many studies of widely
differing design ranges from approximately 50 to 100 %
(Gregory, 1997; Mullin & Duch, 1992; Selhub & Rosen-
berg, 1997).
The number of folate cofactor forms, variable polygluta-
mate chain lengths, and instability of many of the reduced
derivatives have made separation of these complex mixtures
extremely difficult (Mullin & Duch, 1992; Selhub & Rosen-
berg, 1997).
3.1.2. Food analysis. Since the polyglutamated forms of
folate in the diet are hydrolysed to monoglutamates prior to
transportation into the cell it is reasonable to analyse folate
as the monoglutamates in food. Most high-performance
liquid chromatography (HPLC) methods have been
designed for the analysis of folate monoglutamates and sev-
eral methods for chromatographic analysis of folic acid and
its monoglutamate derivatives exist, especially reversed-
phase HPLC methods. There does not appear to be any
trend toward a common method. Many of the HPLC
methods can only separate some of the folate monogluta-
mate derivatives. The choice of detection form is decisive.
Several HPLC studies have been reported to separate stan-
dard solutions of different folate forms, whereas only a few
methods deal with analysis of dietary folates. Besides, no
standardised procedure for the hydrolysis of polyglutamate
folates has been adopted, and the conjugase preparations
differ in sources, activities, optimal pH and hydrolysis pro-
ducts (Mullin & Duch, 1992; Lucock et al. 1995; Wigertz &
Jagerstad, 1995; Truswell & Kounnavong, 1997).
The paucity of information on the bioavailability of food
folates stems principally from the complexity of dietary
folates, their low levels in various foods, the presence of
some dietary factors such as inhibitors of pteroylpolygluta-
mate hydrolase (PPH) that could affect folate bioavailabil-
ity, and the inability to distinguish between newly absorbed
folate and endogenous folates (Gregory, 1997; Selhub &
Rosenberg, 1997). Analysis of native folates is complicated
not only because the vitamin occurs in many different
forms, but also because these folates are light- and heat-sen-
sitive and are easily destroyed by oxidation (Wigertz &
Jagerstad, 1995).
The bioavailability of added folic acid is greater than that
of naturally occurring food folate. Folic acid does not occur
naturally in significant quantities, but is the form of the vita-
min added to foods during fortification, and it is very often
used in studies measuring plasma folate in order to estimate
folate status (Sauberlich et al. 1987; Gregory, 1997).
3.1.3. Choice of matrix for biomarker measurements. It
should be stressed that analysing erythrocyte folate instead
of plasma folate is to be recommended. Plasma folate varies
much depending on recent intakes, changes in folate metab-
olism, and instability over time in plasma. Physiological and
life-style variables, notably alcohol and tobacco use, are
also important determinants of plasma folate. Plasma folate
can be suitable if many other parameters are held constant,
but it is not possible to use plasma folate in population stu-
dies (O’Keefe et al. 1995; Brussard et al. 1997; National
Food Agency of Denmark, 1997; Selhub & Rosenberg,
1997; Stites et al. 1997).
Erythrocyte folate levels reflect body stores and are con-
sidered to be a measure of long-term status. Red blood cell
folate content is about 20 times the concentration of plasma
folate. There are some methodological problems with the
analysis of erythrocyte folate, e.g. erythrocyte folate is
reduced by vitamin B12 deficiency (Brussard et al. 1997;
National Food Agency of Denmark, 1997; O’Keefe et al.
1995; Selhub & Rosenberg, 1997; Stites et al. 1997). Red
cell folate is probably a good indicator to discriminate
between normal folate status and deficiency. However,
under therapeutic conditions or in the evaluation of bio-
availability, there is a need for additional functional tests,
sufficiently sensitive and specific, to reflect rapid changes
of folate status. Elevated concentrations of homocysteine
in serum or plasma is a test that seems promising (Jagerstad
& Pietrzik, 1993; Ueland et al. 1993).
3.1.4. Poly- or monoglutamate form. The folate polyglu-
tamates inside the cell are the true biological cofactors.
Therefore, one could argue that considerable important bio-
logical data are sacrificed with the hydrolysis of polygluta-
mates to the monoglutamates in analysis of intracellular
(e.g. erythrocyte) folate. However, there is not enough
knowledge to link the different intracellular polyglutamates
with the dietary exposure.
3.1.5. Analytical methods. Analysis of intracellular
folates represents a complex analytical problem since
eight potential parent species (folic acid, dihydrofolate,
tetrahydrofolate, 10-formyltetrahydrofolate, 5-formyltetra-
hydrofolate, 5,10-methylenetetrahydrofolate, 5,10-methyl-
tetrahydrofolate, 5-methyltetrahydrofolate) are present in
variable states of polyglutamation. The digestion of these
folate polyglutamates reduces all species to folate monoglu-
tamates, which can then be analysed using methods similar
to those used for food analysis (Mullin & Duch, 1992). The
different forms of monoglutamate folates may have differ-
ent biological activities in both micro-organisms and more
importantly in humans, and it is therefore desirable to sep-
arate the different cofactor forms of folate.
Microbiological assays with the test organism Lacto-
bacillus casei, in which growth response to a mixture of
folates is measured turbidimetrically, can be used. Micro-
biological assays have limitations such as different biologi-
cal activities of the monoglutamate folate forms in the
microorganisms, and only an overall value of the folate
content is gained, and there are great differences in the
measured levels from one laboratory to another (Ek, 1983;
Sauberlich et al. 1987; O’Broin & Kellecher, 1992;
Cuskelly et al. 1996; Kelly et al. 1996; Selhub & Rosen-
berg, 1997; Truswell & Kounnavong, 1997).
For clinical purposes methods based on enzyme-linked
immunoassay (ELISA) and commercial radioimmunoassay
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(RIA) have replaced the microbiological method. These
assays are simpler to perform than microbiological assays
and are not affected by antibiotics. However, the affinities
of different folate monoglutamates for the binding proteins
vary considerably, making this assay method useful only for
those tissues in which one form of folate predominates, e.g.
serum or plasma. In addition their specificity for individual
folate forms has been reported as being not uniform and the
response to conjugated folates is also unclear (Jagerstad &
Pietrzik, 1993; Wigertz & Jagerstad, 1995; Ortega et al.
1996; Quinn & Basu, 1996).
HPLC is the preferred way to measure folate, because
HPLC provides quantitative information of the folate
derivatives. However, HPLC methods can separate relevant
folate forms, only in the form of monoglutamate derivatives
(Lucock et al. 1995; Wigertz & Jagerstad, 1995). No stan-
dardised procedure for the hydrolysis of polyglutamate
folates has been adopted, and the conjugase preparations
differ in sources, activities, optimal pH and hydrolysis pro-
ducts (Wigertz & Jagerstad, 1995).
More complex affinity HPLC methods, which provide
information of the distribution of glutamic acid chain
length, are described, but these are not yet suitable for status
assessment (Selhub, 1991; Selhub & Rosenberg, 1997)
Improving ways to chromatographically speciate folyl-
mono- (and poly)glutamates will open up a new frontier
in understanding one-carbon metabolism in health and
disease.
3.1.6. Conclusions. The link between dietary exposure
and the biomarker can be compromised by several analyti-
cal and methodological problems. For folate the following
should be considered.
. Choice of matrix is very important. It is better to
measure erythrocyte folate than plasma folate.
. Standardisation of HPLC methods is needed.
. Standardised procedures for the hydrolysis of polygluta-
mate folates are needed.
. How many and which derivatives should be measured?
. How does HPLC compare with other methods which
measure total folate?
. There is a great need for a better understanding of folate
bioavailability and the factors that influence it.
3.2. Selenium
3.2.1. Importance of Se. Selenium (Se) is an element which
has attention focused not only on its ability to behave as
both an essential and a toxic element, but also on its putative
role in disease and cancer prevention (Crews, 1998, 2001).
Under ideal conditions, the essential and toxic effects
should be controlled by appropriate dietary intakes of this
element. However, it is not yet clear if the application of
Se in disease prevention will require food fortification or
dietary supplementation with elevated levels of specific
chemical forms of this element. Studies with rodents indi-
cate that Se supplementation, at levels above dietary
requirements, is capable of lowering the incidence of tumori-
genesis induced by chemical carcinogens or viruses
(Diplock, 1993; Ip & Lisk, 1994). A recent human study
indicated that certain cancers were prevented when daily
supplementation with yeast containing Se at 200mg was
given (Clark et al. 1996). This level is above both the United
Kingdom Reference Nutrient Intake (70 and 60mg/day for
men and women, respectively) (Department of Health,
1991) and the United States National Research Council Rec-
ommended Daily Allowance (70 and 55mg/day for men and
women, respectively) (National Research Council, 1989). In
order to understand how best to provide dietary sources for
both essential and disease preventative functions, our
knowledge of, and ability to measure, biomarkers of Se sta-
tus needs some clarification. Diplock (1993) stated that two
factors play an important part in forming a judgement about
the reliability of blood or other tissue measurements of Se as
an index of Se status. Firstly, the methodology for making
the measurement of Se must be reliable and reproducible,
and secondly, it must be established that the variable
measured is directly related to the biochemical variables
for Se activity in vivo.
3.2.2. Possible biomarkers of Se status. Selenium is
essential for many biochemical pathways through a range
of Se-containing proteins, hence there are many potential
indicators of Se status (Arthur, 1999; Crews, 2001). Blood
plasma or serum concentrations can indicate changes in sta-
tus for populations exposed to low or moderate levels of the
element and are commonly used in clinical practice. The
levels can vary widely between populations and are related
to dietary intake (Thomassen & Aaseth, 1989).
It seems reasonably well established that blood plasma Se
will indicate an individual’s status with regard to dietary Se
intake but what of the status with regard to the known sele-
noproteins such as the glutathione (GSH; EC 1.11.1.9) per-
oxidases, Se-protein P, the iodothyronine deiodinases (EC
3.8.1.4) and sperm capsular protein? Arthur & Beckett
(1994) point out that an important consequence of identify-
ing the different glutathione peroxidases is the possibility
that each has a different sensitivity to Se deficiency. For a
better assessment of Se status, blood plasma Se concen-
tration could be used in conjunction with a functional mar-
ker of effect, such as platelet GSH peroxidase activity
(Crews et al. 1997).
However, functional effect assays using GSH have some
limitations. For example, erythrocyte GSH peroxidase
activity represents an easily accessible functional index of
Se status although it offers poor sensitivity to modification.
Increased activity was slow after supplementation of
depleted subjects with 100–200mg Se/day reflecting the
long life span of red blood cells in circulation (Ne`ve & Car-
pentier, 1989); and, platelet GSH activity can reflect recent
changes in intake and body stores rather than long-term sta-
tus (Whanger et al. 1988). In addition, for GSH peroxidase
activity in plasma or blood cells there appears to be a pla-
teau for the Se concentration in blood or plasma beyond
which there is no increase in activity (Marchaluk et al.
1995). For erythrocyte GSH, the peroxidase activity pla-
teaus at plasma Se levels between 0:76 and 0:89mmol/l
and in whole blood at 0:76 and 2:03mmol/l in different
studies (Ne`ve, 1991; Marchaluk et al. 1995); for platelet
GSH activity the plasma Se plateau has been found to be
1:39–1:71mmol/l (Ne`ve, 1991) and 1:25–1:45mmol/l
(Alfthan et al. 1991). In a recent human dietary intervention
study, erythrocyte and plasma GSH peroxidase were found
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not to be sensitive to large changes in Se intake over a six-
week period whereas plasma Se concentrations determined
after intakes of 25 and 425mg/day for six weeks (mean
plasma Se 64:6 and 103:8mg/l, respectively) and platelet
GSH peroxidase activity (for 425mg/day intake, mean
plasma Se 103:8mg/l) were more sensitive indicators of
change in Se status (Fox et al. 2000).
Since the Se content of GSH peroxidase and selenopro-
tein P in plasma can be saturated over the general nutritional
range of intakes, it is not likely to respond to the wide range
of intakes involved in long term Se supplementation
(Janghorbani et al. 1999), which may be used in future dis-
ease prevention therapies. Conversely, on low Se intakes,
adaptation may take the form of redistribution of Se
among selenoproteins when supplements are given. Thus
supplementation may result in Se in plasma being retained
with albumin and not repleting critical pools of Se, because
adaptation will have already ensured that dietary Se goes to
the high priority protein-selenoprotein P (Finley et al.
1999).
A second major class of selenoproteins are the iodothy-
ronine deiodinases which catalyse the conversion of thy-
roxine into its biologically active form, triiodothyronine
and its inactive derivative reverse triiodothyronine (Arthur
et al. 1997). Although a more thorough understanding of
the mechanisms is required, it is possible that measure-
ment of the T4:T3 values (ratio of thyroxine to the active
hormone triiodothyronine) in human plasma may give an
indication of iodothyronine deiodinase activity in other-
wise inaccessible tissues (Olivieri et al. 1995; Arthur,
1999), providing a biomarker for a different aspect of
Se biochemistry.
In summary, the following determinations have been
suggested as useful in assessing functional Se status: plasma
or whole blood Se concentrations, plasma GSH peroxidase
activities, erythrocyte GSH peroxidase activities, Se-peroxi-
dase activities in blood cells (platelets, lymphocytes and
neutrophils), and thyroid hormone levels (Arthur, 1999).
Given the wide range of functions of Se it is unlikely that
any one biomarker will fit all requirements but direct
measurement of Se in whole blood and plasma is currently
the most common way of assessing Se status (Diplock,
1993).
3.2.3. Analytical considerations. Methods for determin-
ing total Se levels are generally well established and, with a
number of certified reference materials now available,
should enable the provision of reliable data. Most methods
of determination (with the exception of purely instrumental
methods such as neutron activation and X-ray fluorescence
analysis) require the sample to be a dissolved mineralised
state (Alt & Messerschmidt, 1988). For human tissues,
wet ashing with acid (nitric and/or sulphuric and/or per-
chloric) is preferred. Extreme care and strictly controlled
procedures are required to prevent losses of Se (Thomassen
& Aaseth, 1989).
However, Reilly (1996) made the point that (in relation
to the measurement of Se for reliable dietary intake data
at both national and regional levels), ‘in spite of the
enthusiasm with which many investigators responded to
this need for information, a good deal of what was published
appeared to be contradictory and of doubtful reliability’.
In the same year, Alfthan & Ne`ve (1996) critically
reviewed published serum and plasma Se data using the
TRACY protocol (an international project for producing
reference values for concentrations of trace elements in
human blood and urine). The TRACY criteria for assessing
the information included the number of subjects and selec-
tion criteria, health status, diet, contamination control and
sample storage and analytical treatment. Of the 36 papers
covered (restricted to those produced in the previous 10
years), no paper received the maximum rating possible. It
was noted that only two set out to determine reference
values and one normal values. The authors write in their
final paragraph: ‘Analytical instruments have improved tre-
mendously during the past decade. Unless they are applied
critically and the results are presented with sufficient back-
ground information on the study population, analytical
reliability and data treatment, published data may be of little
use or even misleading’. Therefore, with regard to plasma
Se as a biomarker of dietary exposure, the validity of the
measurement may comprise the usefulness of the
biomarker.
From an analytical viewpoint, the methods for some func-
tional effect assays (GSH peroxidase activity in whole
blood, serum, plasma and platelets), are less robust than
total Se determinations. It should be noted that the methods
are generally not standardised nor collaboratively tested
(Crews et al. 1997), and variants of two generally accepted
methods (Paglia & Valentine, 1967; Wendel, 1981) are
used. The enzymic techniques for measurement of GSH
activity can be difficult, having limited sensitivity, speci-
ficity and stability, as well as problems in obtaining a con-
stant blank and defining a reference method (Faraji et al.
1987; Whanger et al. 1988; Huang & A˚kesson, 1993). To
further complicate the situation, there may be different
homeostatic mechanisms for activity in different blood frac-
tions (Reilly, 1996). Some radioimmunoassays have been
developed for GSH serum and plasma for example
(Huang & A˚kesson, 1993; Huang et al. 1995). Commercial
kits are available based on radioimmunoassay methods but
these can be expensive, especially when considering popu-
lation studies.
3.2.4. Conclusions. Ideally, if say three different but
robust and well understood measurements of Se status
could be made (e.g. plasma Se, platelet GSH peroxidase
activity and perhaps an assessment of thyroid hormone
activity?), then this ‘battery’ approach might enable individ-
ual Se status to be better defined and requirements for
enhanced health better targeted. Such an approach would
rely on a good understanding of the mechanisms of the vari-
ous roles of Se and established and validated analytical
procedures.
The latter part of this statement applies to all types of ana-
lyses and has added importance when data are used for
informing policies for health and legislation. Selenium is
currently of worldwide interest to the food, pharmaceutical
and nutraceutical industries, to consumers, clinicians and
academics. To make best use of the potential of Se to benefit
human health, it is essential that accurate measurements of
biomarkers for Se exposure and effect are conducted. Varo
et al. (1994) commented that because the changes in disease
rates result from a multitude of other factors, it will be
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difficult to determine whether an increased Se intake influ-
ences the health of a whole nation. Thus, conclusions on the
role of Se in health must be based on experimental and clini-
cal studies, on epidemiological studies with populations and
on controlled clinical trials. Accurately measured and rel-
evant biomarkers of Se status are an essential part of this
process.
4. Effects of metabolism
4.1. Flavonoids
There are many examples of (iso)flavonoids in the diet, but
the most data related to biomarkers of exposure are avail-
able for catechins (flavan-3-ols), quercetin derivatives (fla-
vonols), genistein and daidzein (isoflavonoids). However,
even the data for these compounds derive from only a few
papers. Dietary flavonols and isoflavonoids are usually
ingested as glycosides which can dramatically modify the
biological properties. Further, there are several forms of
catechin which include ester-linked galloyl groups ((+)-
catechin (C), epicatechin (EC), epigallocatechin (EGC)
and epigallocatechin gallate (EGCG)), and these modifi-
cations also change the absorption and biological properties.
4.1.1. Validity or adequacy of the biomarker. Further
modification to the flavonoid is brought about by metab-
olism, which occurs by the intestinal mucosa/liver/kidney
and by the gut microflora. Description of a detailed meta-
bolic pathway for these compounds is not yet possible, but
can involve deglycosylation in the small intestine (Day et al.
1998, 2000) or colon. Alternatively, breakdown in the colon
by microflora and subsequent absorption of flavonoids or
breakdown products such as benzoic and cinnamic acids
can occur, followed by methylation, sulphation and glucur-
onidation of intact flavonoids or breakdown products in tis-
sues such as liver and kidney. Most of the methods for
measuring these metabolites are by HPLC, which especially
with UV detection, is not sensitive enough to measure all of
the metabolites. Further, the biological properties of the
polyphenols are modified by metabolism (Day & William-
son, 2001), which makes prediction of effect difficult. Most
methods so far use chemical or enzymic hydrolysis to con-
vert some of the metabolites back into free aglycone.
Methods for analysis of polyphenols in urine and plasma
employ gas chromatography, or HPLC with various detec-
tors such as UV, mass spectrometric or electrochemical
systems (Hackett et al. 1985; Lee Mao-Jung et al. 1995;
Gross et al. 1996; Unno et al. 1996; Maiani et al. 1997; Naka-
gawa et al. 1997; Nakagawa & Miyazawa, 1997; Paganga
& Rice-Evans, 1997; Mauri et al. 1999). However, the
results have not been validated between laboratories, and
this is hampered by the lack of knowledge on the metab-
olites of most polyphenols in humans. It is also very diffi-
cult to obtain, use and quantify appropriate standards,
especially of the metabolites. As a consequence of this,
there is no reliable and comprehensive source of data for
the content of phenolics in food and drink and often each
country uses different tables. This leads to difficulties in
estimation of the total intakes of phenolics.
There are some data on the intake of selected flavonoids
in different population groups using compositional data
(Hertog et al. 1993, 1997; Hertog & Kromhout, 1995;
Keli et al. 1996; Knekt et al. 1996; Rimm et al. 1996),
but there are no measurements of polyphenols in urine or
plasma from the same studies to accompany this. The data
show that typical intakes of selected flavonoids (quercetin,
kaempferol, myricetin, luteolin and apigenin) are 0–68 mg
per day (Table 1).
An approach has been developed using volunteer ileos-
tomists, to avoid the complication of microbial fermenta-
tion and degradation in the colon which is usually a
complicating factor in determination of metabolism of
polyphenols. As an example, average absorption in the
small intestine of quercetin (present as glycosides) from
onions was 52 % of the total consumed, but most of this
could not be accounted for in the plasma (Table 2) (Holl-
man et al. 1995). However, the method relies on subtrac-
tion of the amount found in the output from the small
intestine from the total consumed.
There is more information on the uptake of isoflavonoids.
As an example, uptake of genistein and daidzein was
measured in 12 female subjects aged 19–41 years (Xia
et al. 1994). The results given in Table 3 show that the con-
centrations of genistein and daidzein in the plasma were up
to 2:2mM, and in urine up to 14 and 6:2mM, respectively,
and that these levels were approximately proportional to
intake.
4.1.2. Conclusions. Research to examine the effect of
flavonoids in vivo in humans is limited compared to nutri-
ents, and there is a need for further work. Future work could
be to establish the half-life after ingestion of habitual dietary
intake of these compounds in human, to establish the mag-
nitude of the potential health effects in relation to other diet-
ary components. It is also important to establish the baseline
habitual level of polyphenols and metabolites in the plasma
or urine in non-supplemented individuals. One of the most
important areas is to elucidate the metabolism so that
measurement of biomarkers can take account of this.
Table 1. Intakes of certain flavonoids in different population groups
Groups population No. of subjects Gender
Age
(years)
Flavonol and flavone intake*
(mg/day) Reference
Zutphen (1993) 805 m 65–84 25:9^14:5 (Hertog et al. 1993)
Finland 5133 m/f 30–69 0–41:4 (Knekt et al. 1996)
USA 34789 m 40–75 7:1–40:0 (Rimm et al. 1996)
UK 1900 m 49–59 26:3^12:5 (Hertog et al. 1997)
Zutphen (1996) 552 m 50–69 23:5^7:6 (Keli et al. 1996)
Seven countries study 12763 m 40–59 2:6–68:2 (Hertog & Kromhout, 1995)
* Quercetin, kaempferol, myricetin, luteolin and apigenin.
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4.2. Carotenoids
4.2.1. Metabolism of a compound may affect the validity of a
biomarker. This problem can be illustrated well by con-
sideration of the carotenoids. More than 600 carotenoids
exist in plants. Approximately 50 of them might be con-
sumed in the human diet, yet only five to seven are found
in serum in significant amounts: these are a- and b-carotene,
b-cryptoxanthin, lycopene, lutein and zeaxanthin. Most of
the available information concerns these compounds
(Krinsky, 1993; Michaud et al. 1998), and b-carotene,
which is the only one to figure in food composition tables.
Yet some others may have interesting properties that would
deserve a more thorough evaluation.
Biomarkers used to evaluate the dietary intake and/or the
protective potential of carotenoids are either the serum caro-
tenoid profile (Cooney et al. 1991) or, to a lesser extent, the
amount of carotenoids in buccal mucosal cells (Peng et al.
1994). However, carotenoids undergo isomerisation or
metabolism, and the resulting compounds, which are often
not identified by usual analytical techniques, may differ in
their biological effects.
4.2.2. Metabolism and isomerisation. Some carotenoids
(mainly a- and b-carotene; b-cryptoxanthin) are able to
produce vitamin A by an enzyme-induced pathway in the
intestine and/or the liver. Retinal is formed by central clea-
vage of the molecule and will be either reduced in retinol or
oxidised in retinoic acid (Nagao et al. 1996). An eccentric
cleavage pathway of provitaminic carotenoids may produce
various apo-carotenals (Wang & Krinsky, 1997). The effi-
ciency of this metabolism is not precisely known, yet it can
affect most of the ingested carotenoid, which may then
represent a large part of the vitamin A supply. Moreover,
there is a high interindividual variability in this cleavage
(Dimitrov et al. 1988). In consequence, the serum level of
provitaminic carotenoids reflects only partly the dietary
intake.
Carotenoids are susceptible to isomerisation, either in
plants, or during storage and processing (Chen et al. 1994;
Doering von et al. 1995). The absorption and subsequent
distribution of these isomers in tissues vary. After ingestion
of a mixture of b-carotene isomers, only the all-trans form
is found in the blood, whereas 13-cis or 9-cis isomers may
represent up to 20 % in some tissues. In contrast, the isomer
pattern is similar in tissue and in serum after ingestion of a
mixture of lycopene isomers (Chen et al. 1994; Doering von
et al. 1995).
In addition, carotenoids such as lycopene or lutein are
metabolised in vivo following oxidation or non-enzymatic
dehydration (Khachik et al. 1995). Most of the routine
HPLC methods for carotenoid analysis do not discriminate
between these isomers or metabolites, and may not give an
accurate estimation of the dietary carotenoid intake (Nelis &
Deleenher, 1983; Bieri et al. 1985; Hart & Scott, 1995).
More specific methods exist which allow the identification
of carotenoid metabolites and/or isomers (Schmitz et al.
1994; Khachik et al. 1997; Lessin et al. 1997). However,
none of these methods has been agreed as a reference
method, nor have any been thoroughly validated.
4.2.3. Antioxidant role. Beyond the difficulties that the
metabolic pathways may add to the evaluation of dietary
exposure to carotenoids, it may also hamper the correct esti-
mation of the biological effects of the carotenoids, and
especially of their antioxidant roles. The antioxidant
potency of one single molecular species is difficult to assess
unequivocally. The results of in vitro studies are conflicting
and some authors suggest that, in vivo, the 9-cis isomer
of b-carotene could be a more efficient antioxidant than the
all-trans form (Schmitz et al. 1991; Schut et al. 1997). The
interaction between the various dietary antioxidants should
Table 2. An example of a study showing flavonoid (quercetin) uptake and metabolism using ileostomist sub-
jects: nine healthy ileostomy subjects received a supplement of fried onions at breakfast (rich in quercetin
glycosides) equivalent to 89 ^ 14 mg quercetin aglycone; nine subjects received pure quercetin rutinoside,
equivalent to 100 ^ 5 mg; and nine subjects received 100 ^ 5 mg of pure quercetin aglycone (Hollman et al.
1995)
Ileostomy effluent* Urine*
Form of dietary flavonoid Before (mg) After (mg) Before (mg) After (mg)
Onion 1:8^1:1 37^11 1:2^1:9 275^129
Quercetin 3-rutinoside 1:3^0:9 72^15 3:6^5:1 73^190
Quercetin aglycone 1:7^1:3 66^9 1:0^1:1 115^75
* Amount of quercetin (as aglycone) over a time period of 13 h after ingestion.
Table 3. An example of a study showing isoflavonoid uptake and absorption in 12 female subjects aged 19–
41 years (Xia et al. 1994)
Dietary intake (mg) Urine after 12–24 h (mM) Plasma after 6.5 h (mM)
Daidzein Genistein Daidzein Genistein Daidzein Genistein
24:7^3:66 19:3^2:9 4:5^3:1 0:93^1:55 0:79^0:04 0:74^0:44
45:9^6:80 36:2^5:4 11:5^10 3:89^6:07 1:22^0:67 1:07^0:63
70:7^10:5 55:7^8:2 14:2^12 6:18^9:77 2:24^1:18 2:15^1:33
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not be underestimated when assessing the protective poten-
tial of carotenoids.
A better knowledge of the metabolism and physiology of
carotenoids is required in order to correlate the level of
serum or tissue carotenoids with their antioxidant potency.
Accurate and validated analytical methods need to be devel-
oped and used in order to adequately compare the data
obtained in different laboratories.
5. Consistency of information from several biomarkers
for one component
5.1. Vitamin A
5.1.1. When assessing exposure to a nutrient or a non-nutri-
ent, the information obtained via several biomarkers could
be inconsistent. An adequate knowledge of the physiology
and metabolism of the compound is needed to correctly
interpret the data. Vitamin A status exemplifies the problem
as it can be assessed by several biomarkers.
5.1.2. Retinol. The most frequently used biomarker is
serum retinol, although it has a major drawback. The retinol
concentration in serum is tightly regulated to be around
2mM, and is not related to the food intake or to the level
of vitamin A body stores (i.e. liver), except in extreme
hypo- or hypervitaminosis A (Underwood, 1994). Another
test estimates both the liver stores and the ability to mobilise
these stores. This is the relative dose-response test (RDR)
which measures the possible transient increase of serum
retinol 5 hours after a physiological oral dose of vitamin
A. Because serum retinol is regulated, it should not vary
during this period, and, in normal conditions, the newly
absorbed vitamin A is stored. However, if the subject’s tis-
sues urgently require vitamin A, the newly absorbed vitamin
A will be immediately mobilised and this will lead to a lim-
ited and transient, but still detectable, increase in serum reti-
nol (Amadee-Manesme et al. 1984).
5.1.3. Impression cytology. A third series of tests inves-
tigate vitamin A-dependent functions. Impression cytology
refers to the role of vitamin A as a protector of epithelia. The
fact that the eye is the organ studied does not mean that
these tests have a link with the biochemistry of vision,
although a severely altered conjunctiva will lead to impaired
vision. This test stains for goblet cell presence in the eye
conjunctiva after collection on a filter paper (Natadisastra
et al. 1987).
5.1.4. Interpretation of two or more biomarkers. When
two or more of these biomarkers are used on the same indi-
vidual or in the same population, it can happen that the
serum retinol is in the normal range whereas the RDR indi-
cates a deficient or worse-than-deficient status, and results
from impression cytology may or may not be in the normal
range. Similarly, other combinations of status may be found
(Ward et al. 1993; Azais-Braesco et al. 1995). These situ-
ations may be the result of the threshold values chosen to
delineate the different measures of status. However, some
discrepancies sometimes remain, even when thresholds are
modified. To overcome these discrepancies, one should
remember the physiological basis of the biomarkers.
Impression cytology detects early functional symptoms of
vitamin A deficiency. Serum retinol reflects only very low
or very high liver vitamin A stores, and gives little infor-
mation about the functionality of these stores. The RDR
estimates the adequacy of the liver stores to fulfil the tissue
requirements and gives information about the metabolic
ability of the organism to mobilise these stores. Retinol is
secreted from the liver bound to retinol-binding protein
(RBP), which has a short half-life of 12 hours. Because
RDR addresses retinol secretion over a short period of
time, it may detect a default in the synthesis or secretion
of RBP, which cannot be seen with a simple measurement
of serum retinol. This could be the case during liver diseases
and protein malnutrition (Russell et al. 1983) or in elderly
people (Bulux et al. 1992). Other pathophysiological con-
ditions, such as infectious or inflammatory diseases, renal
failure and diabetes alter RBP metabolism (Goodman,
1984) and may consequently modify the meaning of the
results of the RDR test. In contrast, serum retinol could be
decreased below normal levels in some situations, e.g. total
parenteral nutrition (Howard et al. 1980), and retinoid
therapy (Formelli et al. 1993), although liver vitamin A
stores are likely to be adequate. In such situations, clinical
symptoms of vitamin A deficiency might be observed.
The information given by one biomarker should therefore
be carefully interpreted. This often requires additional data,
not directly related to the compound, yet necessary to ensure
that the considered biomarker is valid. Whenever possible
the combined use of several biomarkers, should be
favoured. Although vitamin A metabolism has been and is
still being extensively studied, a non-ambiguous biomarker
of vitamin A functional status is still awaited.
6. Effects of individual life-styles
6.1. Vitamin B12
6.1.1. Variation in dietary intake due to different life-styles
may influence the usefulness of the biomarker. This is
exemplified by Vitamin B12 intake from the diets of veg-
etarian and non-vegetarians. All vitamin B12 found in nature
is made by micro-organisms. The vitamin is absent from
plants except when they are contaminated by micro-organ-
isms (Herbert, 1997). Dietary deficiency of vitamin B12 can
result from a strict vegan (all plant food) diet because vita-
min B12 is not synthesised by any plant, nor does any plant
need, use, or store vitamin B12. Vegetarians who include
animal food in their diets (e.g. milk and eggs) ingest ade-
quate amounts of vitamin B12, and if they develop vitamin
B12 deficiency, it is for the same reasons that omnivorous
subjects develop deficiency (Herbert, 1994). Human milk
of women consuming strict vegetarian diets contains signifi-
cantly less vitamin B12 than milk from women consuming
omnivorous diets, and among women consuming vegetarian
diets, milk vitamin B12 concentrations are inversely related
to the length of time a vegetarian diet has been consumed
(Specker et al. 1990; Ford et al. 1996). That vitamin B12
deficiency in some third-world vegan children and adults
is delayed may in part be related to cleanliness. The less
thoroughly hands are washed after defecating and the
more frequently they suck their fingers, the more they pro-
tect themselves against vitamin B12 deficiency (Herbert,
1997).
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6.1.2. Stages of negative cobalamin balance. When the
supply of vitamin B12 is discontinued, four stages of nega-
tive cobalamin status are recognised: stage I, serum
depletion and low holotranscobalamin II (holoTCII), stage
II, cell depletion (low holohaptocorrin and low red cell vita-
min B12 concentrations), stage III, biochemical deficiency
(slowed DNA synthesis, elevated serum homocysteine and
methylmalonate concentrations); stage IV, clinical
deficiency (Herbert, 1994, 1997). Vitamin B12 deficiency
can occur if ingestion (vegetarians), absorption and utilis-
ation are inadequate and if requirement, excretion and
destruction of the vitamin is increased. Depletion precedes
deficiency by months to years. It is possible to diagnose
negative balance at either of the two stages of depletion
(serum and cell depletion) before the negative balance
reaches the stages of deficiency (Herbert, 1994).
6.1.3. Indicators of depletion. Total serum vitamin B12 is
the sum of vitamin B12 bound to the circulating delivery
protein, transcobalamin II (TCII), and vitamin B12 bound
to the circulating storage protein, haptocorrin. TCII delivers
the vitamin to all metabolically active tissues. Total serum
vitamin B12 concentration is a relatively late indicator of
deficiency because normally about 80 % of total serum vita-
min B12 is bound to serum holohaptocorrin, a late indicator,
and only about 20 % is bound to the early indicator, serum
holoTCII. Because TCII is depleted of vitamin B12 within
days after absorption is stopped, the best screening test for
early negative vitamin B12 balance is a measurement of vita-
min B12 bound to TCII (holoTCII). Due to the very short
half-life (6 min) of holoTCII, malabsorption of vitamin
B12 rapidly produces a decrease in the amount of holoTCII
(Das et al. 1991; Tisman et al. 1993; Herbert, 1994; Scott,
1997). Vegans with relatively low total serum vitamin B12,
but no evidence of biochemical or clinical deficiency have
borderline low holoTCII ranging between 40 and 60 pg/ml
(normal range: 200–900 pg/ml; mean: 450 pg/ml) (Herbert,
1994).
6.1.4. Indicators of deficiency. Vitamin B12 functions as
a cofactor for several enzymatic reactions in cellular metab-
olism and, in particular, is needed for the conversion of
methylmalonyl-CoA into succinyl-CoA. Deficiency of vita-
min B12 inhibits this enzymatic conversion and results in an
increase in metabolites such as methylmalonic acid (MMA).
Urinary excretion of MMA in elevated amounts is one indi-
cator of vitamin B12 deficiency (Specker et al. 1990;
Specker, 1994). Besides, measuring urinary MMA levels
makes it possible to distinguish between deficiencies of
folate and vitamin B12, since MMA excretion is not
increased by folate deficiency (Sauberlich et al. 1974).
Another indicator of vitamin B12 deficiency is low total
serum or plasma vitamin B12 concentration (Dagnelie et al.
1989; Miller et al. 1991). Vitamin B12-deficient subjects
may also have increased levels of plasma homocysteine
(Stabler et al. 1990; Hornstra et al. 1998).
6.1.5. Clinical deficiency symptoms. Vitamin B12
deficiency due to a lack of dietary intake of the nutrient is
rare, but can occur among vegans. Such persons may have
low serum levels of vitamin B12, and may develop a sore
tongue, paraesthesias, amenorrhoea, and other signs of a
vitamin B12 deficiency. The classical symptoms of vitamin
B12 deficiency are megaloblastosis, notably macrocytic
anaemia, and/or progressive neurological degeneration
(Sauberlich et al. 1974; Chanarin et al. 1985; Bover &
Wald, 1995; Herbert, 1997). Since most cases of vitamin
B12 deficiency are the result of an impaired absorption of
the vitamin due to lack of the intrinsic factor in the gastric
secretions, vitamin B12 deficiency is more a clinical con-
sideration than a nutritional problem (Sauberlich et al.
1974). Case reports of breast-fed infants of strict vegetarian
mothers, who developed vitamin B12 deficiency resulting in
severe neurological damage, have been published (Specker,
1994).
6.1.6. Reabsorption. The enterohepatic circulation of
vitamin B12 is very important in vitamin B12 economy and
homeostasis. An efficient enterohepatic circulation and sig-
nificant liver stores of vitamin B12 keeps the vegan from
developing B12 deficiency disease for up to 20–30 years
because even as the body store and daily bile vitamin B12
output fall, the amount of bile vitamin B12 reabsorbed
rises to nearly 100 %. Inside the ileal cells reabsorbed, and
food, vitamin B12 is bound to TCII and the resultant holoT-
CII is transported via the bloodstream to all the cells that
need it (Herbert, 1994).
If daily vitamin B12 absorption continues to be less than
daily vitamin B12 loss, negative balance will progress to
stage II, depletion of stores. At this point, many vegans
stabilise for years with depleted stores, because depleted
stores trigger a more efficient absorption of the trace
amounts of vitamin B12 from bacterial contamination of
the small intestine and vitamin B12 secreted in the bile.
Eventually, however, continuing slight negative balance
will deplete vitamin B12 stores, after which stage III nega-
tive balance occurs (Herbert, 1994). The infant of a vegan
mother, who has almost no enterohepatic vitamin B12 cir-
culation because of deficient vitamin B12 liver stores will
rapidly develop vitamin B12 deficiency (Herbert, 1994;
Specker, 1994; Sanders & Reddy, 1994).
6.1.7. Analysis of vitamin B12. For routine assessment
of vitamin B12 nutritional status of individuals, measure-
ment of serum or plasma vitamin B12 content is the first
choice in most laboratories. The tiny quantity of vitamin
B12 activity in human serum can be measured microbio-
logically or by radioassay. Radioassay has many advan-
tages over microbiological assay. About one-third of the
‘vitamin B12’ in serum is in fact not cobalamins, but
other corrinoids, which cannot be used by humans but
may be used by bacteria. Thus, many microbiological
assays find normal vitamin B12 levels in vitamin B12
depleted people because the assay in fact measures non-
cobalamin corrinoids. To avoid this problem, most labora-
tories use competitive inhibition radioassays that measure
only cobalamins. In addition, radioassays are technically
simple, easily standardised and precise, and false low
results do not occur if serum contains antibiotics or
other substances that inhibit growth of microorganisms
(van den Berg, 1993; Whitney & Rolfes, 1996; Herbert,
1997).
The earliest detectable serum marker of negative vitamin
B12 balance is low serum holoTCII. The determination of
holoTCII involves only one additional step in the radioassay
for vitamin B12 (i.e. separation of TCII from haptocorrin by
absorption onto a microfine precipitate of silica). Estimation
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of the vitamin B12 content of the absorbed serum, giving the
vitamin B12 content bound to haptocorrin, and subtraction of
this value from the vitamin B12 content of the untreated
serum, provides the vitamin B12 content bound to TCII
(holoTCII) (Das et al. 1991; Tisman et al. 1993).
6.1.8. Conclusions. Variation in intake can influence the
biomarker. Low intake of vitamin B12 (e.g. vegans) triggers
the reabsorption of vitamin B12, and no useful biomarker of
exposure exists in this case. However, serum holoTCII con-
centration is a good marker of early depletion both in the
case of insufficient absorption and intake.
7. Biological effect monitoring
7.1. Fumonisins
Fumonisin mycotoxins are structurally related compounds,
produced mainly by Fusarium verticillioides (=F. monili-
forme J. Sheld) and F. proliferatum, which occur largely
in maize and maize-based food and feed (Shephard et al.
1996a). Fumonisins in home-grown maize have been
associated with an elevated risk for human oesophageal can-
cer in Transkei, South Africa (Rheeder et al. 1992). These
mycotoxins, due to their structural similarity with sphing-
anine (SA) and sphingosine (SO), intermediate compounds
in the sphingolipid metabolism, cause the inhibition of
sphingolipid biosynthesis through inhibition of the enzyme
sphinganine (sphingosine) N-acyl transferase (also known
as ceramide synthase) (Wang et al. 1991). The result of
this inhibition is an accumulation of free SA and an increase
in the ratio of free SA to free SO in tissues and biological
fluids after exposure to fumonisins (Riley et al. 1994). The
measurement of SA and SA/SO ratio in tissue and biological
fluids is a biomarker for assessing exposure to these myco-
toxins (Riley et al. 1994; Merrill et al. 1996). The sensitivity
of this biomarker to fumonisins has been demonstrated in
different animal species, e.g. pig, rat, horse, poultry, catfish,
rabbit and non-human primates (Wang et al. 1991; Goel
et al. 1994; Riley et al. 1994; Gumprecht et al. 1995; Shep-
hard et al. 1996b). A positive correlation between fumonisin
intake and SA/SO values in rat urine was observed with a
correlation coefficient value of 0:99 (Solfrizzo et al. 1997a).
Measurable concentrations of SO and SA have been
reported from urine of women, whereas low levels or no
measurable concentrations of SA were reported from urine
of men (Castegnaro et al. 1996; Solfrizzo et al. 1997b). The
SA/SO ratio has been determined in plasma and urine of
rural populations in Africa consuming home-grown maize
as their staple diet. No significant difference P . 0:05
was found in the SA/SO ratios between populations living
in regions where mean total fumonisin levels detected in
randomly collected home-grown maize samples were
580 ng/g and ,10 ng/g, respectively (van der Westhuizen
et al. 1999). The need to validate the SA/SO biomarker on
humans has been emphasised in a review on progress in
the development of biomarkers to better assess human
health risks linked with fumonisin exposure (Turner et al.
1999).
Sphinganine and SO can be measured by HPLC-fluor-
escence detection after precolumn derivatisation. The
three published analytical methods for the determination
of SA and SO in animal serum, urine and tissues and
human urine, differ mainly in the clean-up step. In the
first method, the extract is measured by HPLC soon after
sample extraction with ethyl acetate (Castegnaro et al.
1996). In the other two methods, either chloroform is used
for solvent extraction, followed by basic hydrolysis and sev-
eral liquid–liquid clean-up steps (Riley et al. 1994) or a
simple silica gel minicolumn is used to clean-up the sample
before HPLC analysis (Solfrizzo et al. 1997b).
7.1.1. Biological effect. The SA/SO ratio is a good
example of a biomarker of exposure that is also useful for
monitoring the biological effect of fumonisins, as ceramide
synthase is a key enzyme in the sphingolipid metabolism
and sphingolipids have many important functions in cell
membrane. The accumulation of SA caused by the exposure
to fumonisins has been demonstrated to produce a mitogenic
effect that can often affect cell transformation (Schroeder
et al. 1994; Merrill et al. 1996). This effect has been pro-
posed as a plausible molecular mechanism to explain the
carcinogenicity of fumonisins (Schroeder et al. 1994).
7.2. Polyhalogenated aromatic hydrocarbons (PHAHs)
7.2.1. Introduction. Polyhalogenated aromatic hydrocar-
bons (PHAHs) are ubiquitous pollutants that are especially
associated with aquatic food chains. Highest concentrations
are found in those organisms at the top of the food chain
such as fish-eating mammals (Murk et al. 1997) and thus
humans are exposed to these contaminants via dietary
intake. PHAHs are lipophilic persistent compounds and eli-
cit a number of species specific toxic responses in laboratory
and wildlife species. Relatively low residue levels are only
permitted in certain food items (Bovee et al. 1998). Poly-
chlorinated biphenols (PCBs), polychlorinated dibenzo-p-
dioxins (PCDDs) and polychlorinated dibenzofurans
(PCDFs) are present in the environment, not as individual
congeners but as complex mixtures. The relative and abso-
lute concentrations of the individual congeners are continu-
ally changing. This fact makes detection complicated and
also makes it virtually impossible to accurately predict the
biological and toxic potency of these mixtures to animals
and humans. Consequently one problem that scientists
face in the evaluation of risk to PCBs, PCDDs and PCDFs
is the identification and quantification of toxic and/or bio-
active congeners in biological samples. Although the pre-
sent clean-up procedures and high resolution capillary gas
chromatography–mass spectrometry (GC-MS) permit the
separation, identification and quantification of individual
PCDD, PCB and PCDF congeners, these analytical pro-
cedures require highly sophisticated equipment and train-
ing. They are also very costly and time-consuming,
particularly when samples may theoretically contain more
than 200 different PCB, more than 130 different PCDF
and more than 75 different PCDD isomers and congeners.
Additionally, the concentration of these congeners in a
given sample provides only part of the information necess-
ary to evaluate their potential for biological/toxicological
effects in humans and animals. Moreover, even if reliable
congener-specific concentrations in samples can be deter-
mined, it is very difficult to predict their biological effects
because the toxic potencies of the congeners can vary
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significantly, and interactions among various congeners
have exhibited synergism, additivity or antagonism. These
interactions have generally not been considered when
attempts have been made to predict the biological effects
of mixtures. Therefore, from both a human and animal
health standpoint, bioassays capable of detecting and esti-
mating the relative biological or toxic potency of complex
mixtures of PCBs, PCDDs and PCDFs would be extremely
valuable (Brouwer et al. 1995).
7.2.2. Receptor-based assays. Numerous bioassays have
been developed based on arylhydrocarbon-receptor (AhR)-
dependent induction of cytochrome P450 1A1. They utilise
either AhR-containing extracts, or mammalian cell cultures,
to measure a specific biological response (Aarts et al. 1996).
The majority of the AhR-dependent bioassays are based on
measurement of the induction of gene expression. In these
assays, the magnitude of induction by the mixture is
expressed relative to TCDD (total chlorinated dibenzo-p-
dioxins) and the calculated values are then expressed as
TCDD-TEQs (toxic equivalents). Induction assays can be
based on AhR ligand binding, DNA binding, P450
1A1(EROD) induction or induction of a reporter gene.
7.2.3. CALUX assay. Reporter gene assays have been
developed to measure functional inducers via the oestrogen
receptor (ER) as well as the Ah. Recombinant cell lines have
been developed, which exhibit stable AhR- or ER-mediated
firefly (Photinus pyralis ) luciferase gene expression. The
response by, respectively, dioxin or oestradiol in these so-
called CALUX (chemical activated luciferase expression)
assays is dose-dependent and very sensitive, with detection
limits below 1 pM or 0:24 fmol (Legler et al. 1996; Murk
et al. 1996). In addition to measuring the toxic potency of
individual compounds or mixtures, the CALUX assay has
been successfully applied to monitoring AhR- or ER-active
compounds in a variety of matrices, such as human milk and
blood plasma (Aarts et al. 1996; Murk et al. 1997; Bovee
et al. 1998), cow’s milk (Bovee et al. 1998), and growth
promoting agents, veterinary drugs and environmental con-
taminants in food (Hoogenboom et al. 1999).
8. Effects of interactions
8.1. Interpretation of a biomarker is complicated by
interactions
8.1.1. Interactions in the gut. These interactions may mod-
ify biomarkers of exposure of the external dose in the gut or
the internal dose after uptake in the blood. The complex sub-
ject of gastrointestinal physiology and function is well
reviewed in Salminen et al. (1998) in which it is stated
that there is evidence for a strong interaction between the
intestinal microflora, gut mucosa and gut-associated lym-
phoid tissue (part of the mucosal immune system). It is
well known, but not well understood, that diet can alter
the composition of gut microflora (Rowland, 1991). Simi-
larly, the cellular and molecular events by which the diges-
tive flora influences the immune system are poorly
understood and therefore development and validation of
biomarkers is not far advanced. Examples of other inter-
actions in the gut are: the inhibition of resorption of nutri-
ents by antinutritional factors such as protease inhibitors,
lectins or haemaglutinins and lathyrogens present in
beans; the inhibition of toxicity of bile acids by binding to
Ca-phosphate complexes, dilution and increased passage of
bile salts by binding to fibre, and the metabolism affecting
influence of bacterial enzymes in colon (Jacobson, et al.
1984; Potter, 1996; Rijnkels et al. 1997; Rijnkels, 1998; Sal-
minen et al. 1998).
8.1.2. Polyphenols. The synergistic effects of polyphe-
nols have been studied only rarely and the results are not
conclusive (Bors et al. 1996; Terao et al. 1994; Negre-
Salvayre et al. 1995). Ratty & Das (1988) have demon-
strated that flavonoids interact in the polar surface region
of the phospholipid bilayers. It is likely that flavonoids are
localised predominantly near the surface of membranes
where aqueous peroxyl radicals are trapped easily. They
are thus accessible to chain-initiating peroxyl radicals
more readily than a-tocopherol and may prevent the loss
of a-tocopherol. In rats fed with highly peroxidable oils,
the intake of tea catechins prevented a decrease in a-toco-
pherol (Nanjo et al. 1993).
8.1.3. Interactions between antioxidants. Dietary com-
ponents may interact during their absorption and metab-
olism and this interaction complicates the interpretation of
the related biomarkers The in vitro synergistic inhibition of
oxidation by vitamins E and C has been widely reported, as
well as the recycling of tocopheroxyl radical in tocopherol
by ascorbic acid (Niki, 1996). Other studies using in vitro or
animal systems have confirmed a cooperation among anti-
oxidants such as vitamin C, vitamin E and b-carotene. Of
outstanding interest is the co-operation and/or interaction
of b-carotene and vitamin E. Palozza & Krinsky (1991)
have reported that vitamin E and b-carotene have an addi-
tive effect in reducing oxygen radical initiated lipid peroxi-
dation in lipid extract from rat liver microsomes. It has been
suggested that vitamin E increases the beneficial effect of b-
carotene by protecting b-carotene from autoxidation
(Palozza & Krinsky, 1992). Until now, such a metabolic
cooperation has not been demonstrated in vivo, either in ani-
mals or humans. Results obtained in clinical trials regarding
the antioxidant cooperation are contradictory. In a well
conducted study by Blot et al. (1993, 1995) a combination
of b-carotene (15 mg/day), vitamin E (30 mg/day) and sele-
nium (50 mg/day) markedly reduced the incidence of oeso-
phageal and gastric cancer whereas other combinations of
retinol/ zinc, riboflavin/niacin and ascorbic acid/molyb-
denum were not effective. One highly controversial study
from Finland (Heinonen et al. 1994) showed that b-carotene
(20 mg/day), with or without vitamin E acetate (50 mg/ day),
increased the incidence of lung cancer in male subjects with
a chronic smoking habit.
Some experimental studies on humans have reported that
supplementation with one dietary antioxidant modifies the
serum concentration of other natural dietary antioxidants.
However, there is not yet a consistent trend in the results
from various authors. When b-carotene (15–60 mg/day
during 3 or 4 months) is supplied to volunteers, the serum
vitamin E level is decreased in some studies (Xu et al.
1992), whereas it remains stable in others (Willet et al.
1983; Mobarhan et al. 1994; Heinonen et al. 1994; Pappa-
lardo et al. 1997). A b-carotene supplementation
(20 mg/day for 2 years) in patients with colorectal adenomas
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enhances the serum levels of other carotenoids, such as
lycopene or a-carotene (Walquist et al. 1994). The opposite
result was obtained in healthy patients receiving b-carotene
(30 mg/day) during 6 weeks (Micozzi et al. 1992). In one
study, the ingestion of a diet rich in b-carotene, lutein and
lycopene led to a decrease in serum vitamin E (Chopra et al.
1996). It should be pointed out that in epidemiological stu-
dies without supplementation, the plasma concentrations of
b-carotene and a-tocopherol are not correlated (Ascherio
et al. 1992).
8.1.4. Considerations when using biomarkers. The
above examples show that interactions or cooperation
between dietary antioxidants are likely. Yet, it is difficult
to clearly establish the conditions in which they occur;
most of the discrepancies observed between the studies,
especially on humans, might be explained by the differences
in the experimental setting: dosages, duration, sex, age,
pathologies, precise control of all the dietary antioxidants.
However, some hypotheses exist to explain the interactions
observed. They may be due to:
(1) a competition in intestinal absorption (Kayden & Tra-
ber, 1993; Kostic et al. 1995; Parker, 1996);
(2) a competition in serum transport, especially for lipophi-
lic compounds which have to be carried on by lipopro-
teins (Chopra et al. 1996);
(3) a possible sparing effect of one antioxidant by another
one (Xu et al. 1992; Walquist et al. 1994);
(4) a cooperative regeneration of one antioxidant by
another, e.g. vitamin E which is regenerated by vitamin
C (Niki, 1996);
(5) a cooperation between the various antioxidant mol-
ecules, which have different efficacies, in different phy-
sio-chemical environments (aqueous vs. lipohilic,
various oxygen pressures) towards different free radical
species (Burton & Ingold, 1984; Niki, 1996);
(6) an antioxidant or pro-oxidant effect of one antioxidant
present in high concentrations (Blot et al. 1993, 1995;
Goodman et al. 1993; Heinonen et al. 1994; Chopra
et al. 1996).
The following considerations should be remembered
when the serum level of an antioxidant is to be used as a
biomarker. Firstly, the validity of the serum levels of anti-
oxidant dietary components is limited to physiological
levels. Outside the physiological range, the interaction
between the compounds may affect the meaning of circulat-
ing values. This is especially true for lipophilic molecules.
Secondly, when considering the antioxidant status, it is rec-
ommended that all, or as many as possible of the dietary
antioxidant molecules (i.e. vitamin E, vitamin C, major
polyphenols, Se) are considered, rather than one in isolation.
8.2. Total antioxidant capacity (TAC)
Free radical mechanisms are likely to be implicated in the
pathogenesis of many degenerative diseases such as various
types of cancer, cardiovascular and neurological diseases,
cataract and oxidative stress dysfunction (Halliwell,
1996). Free radicals could be scavenged by naturally occur-
ring antioxidants in (target) tissues. Measurement of the
TAC of biological fluids might be useful as a marker for
the ability of antioxidants present in body fluids to prevent
oxidative damage to membranes and other cellular
components.
There is an increasing amount of data indicating that var-
ious dietary constituents or supplemental ingredients act as
‘antioxidants’. These antioxidants are often implicated in
the prevention of various diseases (Halliwell, 1987). For
some, e.g. a-tocopherol, there are sound in vivo data
whereas for others, e.g. wine flavonoids or carotenoids,
data to support their effectiveness in vivo in humans are
limited.
8.2.1. Non-specificity. Antioxidants cooperate in the
defence against oxidative stress, therefore assessing one
antioxidant in isolation from the others is mainly for
mechanistic purposes. Interest has therefore been focused
on measurement of TAC in biological matrices and effects
of dietary factors. The antioxidant capacity of biological
samples can be monitored by a variety of simple, non-
specific, screenings assays. These assays are scavenging
assays using relatively ‘stable’ synthetic free radicals (e.g.
ABTS), or reactive ‘natural’ occurring radicals (e.g. OH
.
or
O2
.2). The TAC of biological samples can also be evaluated
in clinical studies which measure endproducts of free-rad-
ical damage of endogenous compounds such as lipids or
DNA. Changes from the baseline levels of these products
could then be ascribed to changes in the antioxidant capacity
of the diet. A general problem with these assays is that they
are poorly validated, and therefore, their specificity as bio-
markers is still under debate.
8.3. Scavenging assays using ‘stable’ synthetic free radicals
8.3.1. Trolox equivalent antioxidant capacity (TEAC). The
TEAC assay is used for measurement of the TAC of biologi-
cal matrices such as plasma and serum. It is a spectrophoto-
metric detection method based on scavenging of long-lived
radical anions (ABTS
.2). All compounds, present in the
serum or plasma, that are able to scavenge the radicals are
detected as potential antioxidants. The greater part of the
activity of serum or plasma (approximately 80 %) is
ascribed to albumin and urate (Wayner et al. 1987), thus
effects of antioxidant supplementation are relatively small.
Differences in serum TEACs have been described in criti-
cally ill patients (Dasgupta et al. 1997), but effects of anti-
oxidant supplementation on the assay are still controversial
(Maxwell et al. 1994; Ryan et al. 1997).
8.3.2. Oxygen radical absorbance capacity (ORAC).
The ORAC assay is a relatively simple, but sensitive
method, and can be used for quantifying the oxygen radical
absorbance capacity of antioxidants in biological tissues
(Cao et al. 1993). In this assay, b-phycoerythrin is used as
an indicator protein and 2,20-azobis(2-amidinopropane)
dihydrochloride as a peroxyl radical generator. This assay
is unique because the reaction goes to completion so that
both inhibition time and inhibition degree are considered
in quantifying ORAC. The ORAC assay has high specificity
and responds to numerous antioxidants (Cao & Prior, 1998).
By utilising different extraction techniques in sample
preparation, one can remove serum proteins making the
ORAC assay more sensitive for antioxidant changes in
serum or plasma.
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8.3.3. 1-diphenyl-2-picrylhydrazyl (DPPH) free radical
method. The relatively stable DPPH free radical is used
for antioxidant activity measurements of lipid-soluble com-
pounds. The disappearance of the radical can be followed
spectrophotometrically and expressed as radical scavenging
ability (Bondet et al. 1997). Interpretation of the assay could
be complicated if the absorption spectra of the test com-
pounds overlap with the DPPH spectrum (515 nm) as with
compounds such as carotenoids (Noruma et al. 1997).
8.3.4. Ferric reducing ability (FRAP) assay. This is a
simple, automated test measuring the ferric reducing ability
of plasma. This assay has been presented as a novel method
for assessing ‘antioxidant power’ (Benzie & Strain, 1996).
Ferric to ferrous ion reduction at low pH causes a coloured
ferrous-tripyridyltriazine complex to form. FRAP values are
obtained by comparing the change in absorbance. This assay
is simple and inexpensive but does not measure the sulphy-
dryl group-containing antioxidants (Cao & Prior, 1998). The
antioxidant capacity of an antioxidant against a free radical
does not necessarily match its ability to reduce Fe3+ to Fe2+.
Interpretation of the assay could be complicated since the
reaction of iron is also involved in free radical generation
processes, e.g. the catalysed generation of OH
.
from H2O2.
8.4. Scavenging assays with specific radicals
8.4.1. Hydroxyl and superoxide radical scavenging.
Scavenging by the hydroxyl radical (OH
.
) and the superox-
ide radical (O2
.2) can be measured indirectly. In the OH
.
scavenging assay, or the ‘deoxyribose assay’, OH
.
radicals
are generated from hydrogen peroxide, ascorbate and FeCl3.
Scavenging activity can be assessed by measuring compe-
tition between the test compound with deoxyribose for
hydroxyl radicals (Halliwell et al. 1987). However, artifacts
may occur with this test as some substances can rapidly
react with hydrogen peroxide. Also powerful iron-chelators
cannot be used in this assay as the compounds interfere with
the measurement products.
In the superoxide radical scavenging assay, O2
.2 is gen-
erated from xanthine/xanthine oxidase (X/XO) and scaven-
ging can be measured by reaction of O2
.2 with cytochrome
c or nitroblue tetrazolium (Halliwell, 1985). Also this assay
is sensitive to artifacts which include inhibition of xanthine
oxidase or reduction of cytochrome c or nitroblue tetrazo-
lium. High absorbance at 290 nm of the test compound(s), or
radicals formed by the test compound after scavenging O2
.2
that reduces cytochrome c or nitroblue tetrazolium also
interfere.
Scavenging of various free radicals, such as OH
.
and O2
2,
can be assessed using highly sensitive electron spin reson-
ance with a spin trap (Noda et al. 1997). Using this tech-
nique, radical scavenging activity of several body fluids
can be measured by normalising the signals relative to the
standard activity of vitamin C or a stable water-soluble ana-
logue of vitamin E. This method is less prone to artifacts,
but more laborious.
8.4.2. Other scavenging assays. The LDL oxidisability
test, measuring LDL lipoprotein oxidation, is often used to
assess antioxidant capacity (Esterbauer et al. 1992). LDL
oxidation is initiated by free radicals. During this pro-
cess, the rate of oxidation is dependent on endogenous
antioxidants in LDL, accounting for the lag-phase of oxi-
dation. LDL oxidation is efficiently inhibited by lipophilic
antioxidants of which a-tocopherol appears to be the most
important. Epidemiological studies suggest preventive
effects towards atherogenic lesions to be associated with
an increased uptake of lipophilic antioxidants such as vita-
min E and carotenoids (Rimm et al. 1993). It is not clear
whether this assay determines additional unidentified com-
ponents and it is also suggested that the results are affected by
the methods applied for isolating LDL (Diplock et al. 1998).
8.5. Damage assays
Instead of scavenging assays, damage to DNA, proteins and
lipids can also be used for monitoring total antioxidant
capacity.
8.5.1. Oxidative DNA damage. Oxidative DNA damage
can be characterised ex vivo by measuring modified DNA
bases as a result of severe reactive oxygen species (ROS)
attack on DNA. The most exploited DNA lesion that is
used as an index of oxidative DNA damage is 8-hydroxy-
deoxyguanosine (8-OHdG) (Loft et al. 1994). This product
is a result of free radical attack on guanine and may be a
useful marker of damage on DNA since it is excreted in
urine. For measurement of urinary 8-OHdG, liquid chroma-
tography (HPLC) with electron capture detection (Shigen-
aga et al. 1994; Verhagen et al. 1997a) is the most
frequently used method.
The validity of this urinary measurement is supported by
the fact that the level of 8-OHdG is presumably not changed
by the diet since nucleosides are not absorbed from the gut.
Thus excretion is presumed to reflect integrated endogenous
DNA damage. However, it is possible that some or all of the
8-OHdG excreted in the urine may arise from deoxyGTP
(Diplock et al. 1998).
Analysis of 8-OHdG in DNA, most notably from lympho-
cytes, has been done but is hampered severely by the fact
that artificial formation during sample clean-up overwhelms
the background levels (some say by up to 2 orders of mag-
nitude; Verhagen, 1998). New approaches are being devel-
oped for measuring 8-OHdG using immunoaffinity assays
and liquid chromatography–tandem mass spectrometry.
8.5.2. COMET assay. Another technique for measuring
antioxidant capacity by evaluating DNA damage is the
‘COMET’ assay (Duthie et al. 1996). This assay measures
DNA damage, i.e. DNA breaks, in cells, e.g. lymphocytes
(Betti et al. 1993; Anderson et al. 1994). DNA damage
(i.e. breaks) can be visualised by staining and unwinding
electrophoresis of the DNA. The assay can be quantified
by scoring of fluorescence intensity of the tails. The sensi-
tivity of this technique can be improved by the use of DNA
restriction enzymes (e.g. endonuclease III) converting the
oxidised bases into strand breaks (Duthie et al. 1996). Diet-
ary studies, performed with the COMET assay, show a posi-
tive effect of antioxidative food components on the
endogenous DNA damage (Collins et al. 1995).
8.5.3. Oxidative damage to proteins. Oxidative damage
to proteins may also be of importance in vivo because it may
affect receptor function, enzyme activity or transport mech-
anisms and may contribute to secondary damage to other
biomolecules, such as inactivation of DNA repair enzymes.
H. Crews et al.S18
Attack by various ROS on tyrosine might result in the pro-
duction of 3-nitrotyrosine that can be measured immuno-
logically or by HPLC or GC/MS (van der Vliet et al.
1996). Nitrotyrosine is excreted in urine (Ohshima et al.
1990), although the possible confounding effect of dietary
nitrotyrosines and of dietary nitrate and/or nitrite is yet to be
evaluated.
More use has been made of the carbonyl assay (Levin
et al. 1995), a non-specific assay of oxidative protein
damage to assess ‘steady-state’ protein damage in human
tissues and body fluids. The carbonyl assay is based on
the reaction of ROS with amino acid residues in proteins
(particularly histidine, arginine, lysine and proline) giving
carbonyl functions that can be measured after the reaction
with 2,4-dinitrophenylhydrazine or by antibodies. Measure-
ment of carbonyls in human plasma can be a useful marker
in nutritional studies, but more work has to be done to ident-
ify the molecular nature of the protein carbonyls in human
plasma.
8.5.4. Lipid peroxidation. A range of methods is avail-
able for measurement of markers of lipid peroxidation and
products of lipid oxidation in vivo. ‘Whole body’ lipid per-
oxidation has been determined by measuring hydrocarbon
gases (ethane, pentane) in exhaled air and urinary secretion
of thiobarbituric acid reactive substances (TBARS) (Gutter-
idge & Thickner, 1978). Hydrocarbon gas exhalation has
too many confounding variables to be applicable in free-liv-
ing human subjects (Springfield & Levitt, 1994). Urinary
TBARS is also not a suitable assay to assess whole-body
lipid peroxidation in response to changes in dietary compo-
sition (Dhanakoti & Draper, 1987), because many artificial
products could be generated. HPLC detection can be used to
separate the ‘true’ malondialdehyde adduct.
Identification of peroxides formed as a consequence of in
vivo oxidative stress can be assessed by a number of
methods, such as the xylenol orange or iodometric methods
(Jiang et al. 1992; Thomas et al. 1989).
Other products of lipid peroxidation that can also be
measured are 4-hydroxynonenal (Douki & Ames, 1994)
and probably the most specific product F2-isoprostanes
(Morrow & Roberts, 1994). F2-isoprostanes can be
measured in plasma and urine of healthy volunteers with
GC-MS and radioimmunoassay (Basu, 1998) and are
indicative of ongoing lipid peroxidation in healthy human
subjects. This urinary marker of lipid oxidation as an indi-
cator of whole body lipid peroxidation has to be further
developed but is highly promising.
8.6. ‘New’ functional redox-controlled assays
8.6.1. Activation of transcription factors. Electromobility
shift assay is a ‘new’ approach that could be used in asses-
sing TAC. Transcription factors (e.g. AP-1 and NF kappaB)
have been implicated in the inducible expression of a variety
of genes, involved in inflammatory and immune responses,
in response to oxidative stress (Sen & Packer, 1996). It has
been found that activation of transcription factors are redox
regulated and can be inhibited by antioxidants (Pinkus et al.
1996). Using human T-lymphocytes, basal activation of
transcription factors can be determined and changes caused
by dietary modulation can be measured as total antioxidant
capacity. Increased activation has already been shown in
patients with leprosy (Zea et al. 1998), sepsis (Bo¨hrer
et al. 1997) and with type-1 diabetes (Hofmann et al. 1998).
8.7. Gaps in area of TAC
There is a great need for standardisation and validation of
these simple screening assays. A clear extrapolation of these
results to the normal physiological situation is not yet avail-
able, but the use of different assays instead of one might
provide a better index of the antioxidant status. The same
applies to the ‘damage’ assays, as overestimation might
occur with these assays and lead to incorrect interpretation
of the results. It should be kept in mind that all these assays
reflect only a single aspect, i.e. scavenging of one type of
radical or total antioxidant capacity. Combinations of the
scavenging and damage assays might provide more infor-
mation about the TAC than either one of them. ‘New’ assays
on activation of transcription factors look promising, but
they need further experimentation.
9. Biomarkers for aflatoxin exposure and effect
9.1. Introduction
Aflatoxins are naturally occurring mycotoxins produced
mainly by Aspergillus flavus and A. parasiticus. Dietary
contamination is ubiquitous in areas of the world with hot,
humid climates, although humans can be exposed to these
toxins everywhere due to the globalisation of food markets.
Human hepatocarcinogenicity of aflatoxins has been defi-
nitely established by the International Agency for Research
on Cancer and World Health Organization (IARC-WHO,
1993). Aflatoxins have been shown to produce liver cancer
and acute hepatic toxicity in humans although they are also
proposed as a risk factor for other diseases such as kwa-
shiorkor (protein-energy malnutrition) and Reye’s syn-
drome (Hall & Wild, 1994). Acute hepatic toxicity
produced by aflatoxins causes histological changes in the
human liver that consists of centrolobular lesions character-
ised by loss of retainable cytoplasm, with areas of liver cell
necrosis, polymorphonuclear neutrophil infiltration and
mild fatty changes in midzonal cells. These observations
were made on the liver of a 15-year-old boy who died of
acute hepatic toxicity linked to the consumption of mouldy
cassava containing 1:7 mg/kg of aflatoxins (IARC-WHO,
1993).
These mycotoxins are among the few environmental car-
cinogens for which quantitative risk assessments have been
attempted (Groopman et al. 1996). This goal was achieved
by the use of specific and sensitive biomarkers in epidemio-
logical studies. The development of molecular biomarkers
for aflatoxins is based on the extensive research data avail-
able on the metabolism, macromolecular adduct formation,
and general mechanisms of action of these toxins both in
experimental and human studies (Eaton et al. 1994; Groop-
man, 1994; Hsieh & Wong, 1994; Groopman et al. 1996).
The rationale for molecular biomarkers can be exempli-
fied by the relation between aflatoxin in the diet and liver
cancer. External exposure can be measured by analysing
foods for their aflatoxin content and by assessing individual
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daily intake of each food by interview. Measurement of this
exposure is particularly difficult. Thus, assessment of
exposure based on food intake is problematic, even given
newer, more specific, methods of aflatoxin measurement
(Hall & Wild, 1994).
9.2. Biomarkers of exposure
Internal exposure to aflatoxins can be assessed by measuring
aflatoxin M1, (AFM1) an oxidative metabolite of aflatoxin
B1 (AFB1), in urine or in milk. AFM1 is the 9a-hydroxy
form of AFB1 and is one of the most predominant aflatoxin
metabolites in human urine. It is formed by the oxidation of
AFB1 by microsomal cytochrome P450 and is excreted in
urine at an amount between 1:2 and 2:2 % of dietary
AFB1 (Groopman, 1994). A human study conducted in
China with a total of 252 urine samples showed a reasonable
correlation r  0:65 between total dietary AFB1 intake
and total AFM1 excretion in urine during a 3-day period
(Zhu et al. 1987). AFM1 can also be measured in human
milk. Estimates of the percentage of aflatoxin in the diet
excreted as AFM1 in milk ranged from 0:09 to 0:43 %
(Groopman, 1994). The measurement of AFB1 in blood
also gives information on internal dose in humans although
it reflects only recent exposure.
9.3. Biomarkers of aflatoxin exposure and effect
9.3.1. Biologically effective dose markers. The biologically
effective dose represents a relevant interaction between a
substance and a body component. It can be defined as the
amount of material interacting with subcellular, cellular
and tissue targets or with an established surrogate (van Pop-
pel et al. 1997). Among the various markers of biologically
effective dose of aflatoxins, the measurement of DNA
adducts (e.g. AFB1-N
7-guanine) is of primary interest
because these adducts represent damage to a critical macro-
molecular target. AFB1-albumin adducts are also very use-
ful because they are surrogate measures of covalent binding
to DNA. Because their half-life is longer than that of AFB1-
N7-guanine, these markers can reveal exposure integrated
over longer time period (Groopman, 1994). AFB1 is metab-
olised in the liver by cytochrome P450 enzyme which pro-
duces, together with other metabolites, a highly reactive
AFB1-8,9-epoxide metabolite that can covalently interact
with nucleophilic centres such as DNA and serum albumin
to form AFB1-N
7-guanine and AFB1-albumin adducts
(Groopman et al. 1992a). Both urinary AFB1-N
7-guanine
and serum AFB1-albumin adducts appear to reflect DNA
damage in the hepatocytes in an experimental system
(Wild et al. 1986).
9.3.2. AFB1-N
7-guanine. The primary AFB1-DNA
adduct is AFB1-N
7-guanine which is removed from DNA
rapidly (half-life 8–10 h) and is excreted exclusively in
urine (Groopman, 1994). AFB1-N
7-guanine is measured in
urine samples using chromatography. Human urine samples
are purified on Sep-Pak C18 cartridge, then purified using an
immunoaffinity column and finally analysed by reversed
phase HPLC with UV diode array detection (Groopman
et al. 1992a,b, 1993). The use of urinary AFB1-N7-Gua
adduct as a biomarker has been validated in the laboratory
and with human sample analyses, and provides a measure of
acute exposure to aflatoxin B1 (AFB1) and reflects relatively
short-term (24–48 h) exposure (Groopman et al. 1992a,b,
1993). In particular, a pilot study on humans showed that
urinary AFB1-N
7-guanine excretion and AFB1 intake from
the previous day had a correlation coefficient of 0:65 and
P , 0:000001: The examination of the dose–response
characteristics for AFB1-N
7-guanine in urine of people liv-
ing in China and the Gambia, with high incidence of liver
cancer, showed the same excellent association of this bio-
marker with exposure (Groopman et al. 1992a, 1993;
Qian et al. 1994). Although this measure is excellent for stu-
dies of acute exposure, it does not reflect chronic intake by
individuals or by a populations (Hall & Wild, 1994).
9.3.3. AFB1-albumin. AFB1 binds quantitatively to per-
ipheral blood albumin in rats in relation to dose. Upon
repeated exposure, accumulation of binding occurs and
the level of albumin binding parallels the binding to liver
DNA (Wild et al. 1986). The major albumin adduct in rats
has been characterised as an AFB1-lysine residue (Sabbioni,
1990). The long half-life of albumin in humans (about 20
days) provides for a measure of human exposure to aflatoxin
over the previous 2–3 months (Wild et al. 1996; Hall &
Wild, 1994).
Complementary ELISA and HPLC–fluorescence tech-
niques are currently used to assay the AFB1-albumin
adducts (Wild et al. 1990a). AFB1-albumin adducts from
serum are hydrolysed and aflatoxin residues are purified
on Sep-Pak C18 cartridge and quantified by competitive
ELISA against an AFB1-lysine standard. For HPLC-based
analyses, AFB1-albumin adducts from serum are hydro-
lysed, purified on immunoaffinity column and the AFB1-
lysine adduct is quantified by reversed phase HPLC with
fluorescence detection. The ELISA measures the total
AFB1-albumin adducts whereas HPLC measures only the
AFB1-lysine adduct. Therefore the ELISA results are
11-fold higher than HPLC results for the same tested sample
(Wild et al. 1990a).
However, this biomarker provides some measurement of
chronic exposure that is not available from other markers
such as the AFB-N7-Gua in urine. Moreover the measure-
ment of serum AFB1-albumin adducts provides a much bet-
ter description of the average exposure avoiding daily
fluctuations of results (Hall & Wild, 1994). The use of
serum AFB1-albumin adducts as biomarkers has been vali-
dated in experimental and human sample analyses (Wild
et al. 1990a, b, 1992). In particular a study performed on
20 residents of Gambia showed a significant correlation
r  0:55 P , 0:05 between the dietary intake of afla-
toxins and the level of albumin-bound aflatoxin at the end
of the study (Wild et al. 1992). Other molecular epidemio-
logical studies confirmed that serum AFB1-albumin is a sen-
sitive and specific biomarker for assessing exposure to
aflatoxin in the population (Wild et al. 1990b; Groopman
et al. 1996; Wang et al. 1996).
9.3.4. AF biomarkers in disease-aetiology. The use of
serum AFB1-albumin adducts and urine AFB1-N
7-guanine
biomarkers in epidemiological studies enabled the role of
confounding factors in the aetiology of liver cancer, such
as hepatitis B surface antigen (HBsAg), to be explained
(Wang et al. 1996). These studies demonstrated that both
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HBsAg and aflatoxin exposure are risk factors for develop-
ing human liver cancer and that people positive for HBsAg,
and exposed to aflatoxins, are much more likely to develop
liver cancer. In particular, results from the epidemiological
studies where both aflatoxin biomarkers and HBsAg were
analysed, showed that the relative risk for liver cancer
was 3:4, 7 and 59 for individuals found positive for aflatoxin
biomarker, HBsAg and aflatoxin biomarker+HBsAg,
respectively (Ross et al. 1992; Qia et al. 1994).
An example of the early biological effect in humans
exposed to aflatoxins is the mutation of the tumour suppres-
sor gene p53, which is the most common mutated gene
detected in human cancers (Groopman, 1994). Two inde-
pendent studies of p53 mutations in hepatocellular carcin-
omas occurring in populations exposed to aflatoxin
revealed high frequencies of G~T transversions, with cluster-
ing at codon 249, whereas the same study conducted in
hepatocellular carcinomas from Japan, and other areas in
which little exposure to aflatoxin occurs, revealed no
mutations at codon 249 (Groopman, 1994).
9.4. Biomarkers of susceptibility
Along the whole path from exposure to disease, the level of
exposure plays a role but also there is genotypic or pheno-
typic predisposition. A sensitivity/susceptibility marker
determines an individual’s inherited or acquired trait that
may predispose them to an increased risk of developing dis-
ease (van Poppel et al. 1997). Cytochrome P450 3A4 is a
major hepatic enzyme involved in the bioactivation of
AFB1, benzo[a]pyrene diol epoxide and several other carci-
nogens. Liver samples with increasing levels of this enzyme
produced higher amounts of AFB1-N
7-guanine in DNA in
vitro. A biomarker for the phenotypic determination of cyto-
chrome P450 3A4 has been reported. In particular, the ratio
of 6b-hydroxycortisol to cortisol is a marker used to assess
the activity of cytochrome P450 3A4 (Groopman, 1994).
This is a useful biomarker for assessing individual suscep-
tibility to AFB1 as well as to many other carcinogens. The
liver is the usual target organ for both acute and chronic tox-
icity of aflatoxins. An immunosuppressive effect of these
compounds has been demonstrated in laboratory animals
which suggests that examination in more detail of putative
immunosuppressive effects of aflatoxins in humans is
required (Hall & Wild, 1994). The long-term goal of the
research in the field of aflatoxin biomarkers is the appli-
cation of biomarkers to the development of preventive inter-
ventions for use in human populations at high risk for cancer
(Groopman et al. 1996).
10. Development of biomarkers – what are the gaps and
why is the information needed?
10.1. Introduction
In contrast to most nutrients, there is a marked lack of bio-
markers of either exposure or effect for most non-nutrients.
For classes of non-nutrients which contain a large number of
examples, such as polyphenols or glucosinolates, there are
data for only a very limited number of representatives (Men-
nicke et al. 1983, 1988; Chung et al. 1992a; Jiao et al.
1994), and there are large numbers of (potentially) import-
ant dietary compounds for which no biomarkers exist at all.
Such biomarkers are essential to examine the predicted
effects (both positive and negative) on health of non-nutri-
ents, which have been implied from a range of epidemiolo-
gical, toxicological, animal and cellular studies (Zhang et al.
1992; Sharma et al. 1994; Zhang & Talalay, 1994; Ozier-
enski, 1994, 1995; Tawfiq et al. 1995). Interpretation of bio-
markers of effect are hampered by lack of knowledge on the
metabolism of most non-nutrients and their mechanisms of
action in humans in vivo. Although some non-nutrients are
predicted to have positive health benefits at dietary concen-
trations, at higher levels there may be toxicity or antinutri-
tional effects (as seen for some studies on b-carotene, see
above). For ethical reasons, therefore, it is not possible to
use high amounts of purified non-nutrients with humans,
although most animal experiments have been performed at
relatively or very high levels (Ioannou et al. 1984). Some
studies have been performed using whole food (Bogaards
et al. 1994; Duncan, 1997), but the complexity of the
material and the presence of other components makes it dif-
ficult to interpret the results.
There is a wide variation in the contents of non-nutrients
in foods, especially where the compounds in question are
derived from processing or cooking of the food, or where
storage of the food affects the components. Reliable tables
of compositional data either do not exist or are not possible
to construct. These factors make it difficult to conduct epi-
demiological or intake studies in populations.
There are only a few studies to date which have addressed
bioavailability of most non-nutrients. Of these, many do not
measure dose–response, and so a validation of the link
between the measured biomarker and the dietary intake is
not established. For many of the non-nutrient compounds,
there is a real lack of information on how much is absorbed,
the amount that enters target cells and tissues and in what
form (e.g. free, protein-bound, conjugated or glycosylated),
and the existence of possible interactions (additive or syner-
gistic) between compounds. For these reasons, there is very
little information reflecting long term exposure, especially
for substances which give rise to highly reactive metab-
olites, since in these cases, only stable endproducts in
plasma or urine can be measured.
There is a lack of standardisation of methodology for the
non-nutrients with few accredited or interlaboratory
methods. Often the detection limits are not sufficient for stu-
dies which employ realistic dietary intakes as opposed to
high levels.
10.2. Glucosinolates
Glucosinolates are a group of secondary plant metabolites
found in Brassicaceae (e.g. cabbage, broccoli, Brussels
sprouts, cauliflower, mustard, horseradish, watercress) and
are b-thioglycosides of which the aglycone is a (Z)-
N-hydroximine sulphate ester. There is a wide range of
side-chains which give rise to a large number of individual
glucosinolates. During processing, cooking and eating,
these compounds are degraded to an even larger number
of compounds, such as isothiocyanates, nitriles, epithioni-
trile and indoles, many of which are bioactive (Plumb
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et al. 1996; Fenwick et al. 1983, 1989). There are bio-
markers of exposure only for certain isothiocyanates
(allyl-, benzyl- and phenethyl-) (Brusewitz et al. 1977;
Mennicke et al. 1983, 1988; Ioannou et al. 1984; Eklind
et al. 1990; Chung et al. 1992a; Jiao et al. 1994; Duncan,
1997). The potent bioactivities (measured in animal models
or at the cellular level) of many of these breakdown pro-
ducts need to be demonstrated in vivo; therefore, biomarkers
of both exposure and effect are required but interpretation is
complicated by the existence of large numbers of break-
down products and their metabolites.
Biomarkers of exposure include N-acetyl cysteine con-
jugates of isothiocyanates in urine. However, the methods
used have not been validated or standardised between lab-
oratories, and were on a small number of volunteers. There
is a need for development of methods which would be
capable of measuring biomarkers of exposure to several
glucosinolates simultaneously, such as estimation of
mercapturic or hippuric acid derivatives. There are very
few data on the bioavailability of these compounds, and in
particular information is needed on the correlation between
the biomarkers and the dietary intake.
Interest in biomarkers for glucosinolates arises from the
proposed biological effects of the breakdown products of
these compounds. The putative beneficial effect of cruci-
ferous vegetables in particular is supported by the results
of many case-control studies (Tables 4 and 5), unlike cohort
studies in which this effect has not (yet?) been established
(reviewed in Verhoeven et al. 1996, 1997a). Mechanisms
involved in chemopreventive action of the glucosinolate
breakdown products indoles and isothiocyanates are anti-
oxidant activity, modulation of biotransformation enzymes,
and modifying binding of carcinogens to DNA. In addition,
indoles may affect the development of hormone-related can-
cers by modulation of the metabolism of oestrogen
(reviewed in Verhoeven et al. 1997b). There are ample
data on the effects of cruciferous vegetables, glucosinolates
and their breakdown products in in vitro studies and in stu-
dies with experimental animals. In contrast, the majority of
human data are from epidemiological studies and the indi-
cations towards the chemopreventive potential of crucifer-
ous vegetables in humans is strong (see above), but the
number of experimental studies on cruciferous vegetables
in humans is very limited. In principle, biomarkers of the
effect of glucosinolate breakdown products are closely
related to the following mechanisms (see Table 6).
(1) Induction of (detoxification) biotransformation
enzymes by Brussels sprouts, e.g. glutathione-S-trans-
ferase (Bogaards et al. 1994; Nijhoff et al. 1995).
(2) Inhibition of oxidative damage to tissue macro-
molecules by Brussels sprouts (e.g. levels of 8-oxo-
7,8-dihydro-20-deoxyguanosine (8-oxodG) in urine
(Verhagen et al. 1995).
(3) Inhibition of carcinogen activation and carcinogen–
DNA formation (e.g. inhibition of the oxidative
metabolism of the lung carcinogen NNK (4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanone)) (Hecht, 1996a)
Table 4. Summary of the results of case-control studies concerning an association between consumption of brassica vegetables and cancer
development; data shown for different vegetables (adapted from Verhoeven et al. 1996)
Number of studies showing an association (of which
statistically significant) Number of studies
showing a different
association by gender
Total number
of studiesType of brassica Inverse association No association Positive association
All types 39 (20) 4 9 (1) 1: inv./pos. 58
1: no/pos.
4: pos./inv.
Cabbage (excl. Chinese cabbage) 17 (7) 5 2 (1) 24
Broccoli 10 (7) 3 1 (0) 1: inv./no 18
2: no/inv.
1: pos./no
Cauliflower 8 (2) 1 2 (0) 1: pos./no 12
Brussels sprouts 2 (0) 2 2 (0) 1: pos./inv. 7
inv., inverse; pos., positive; no, no association.
Table 5. Summary of the results of case-control studies concerning an association between consumption of brassica veg-
etables and cancer development; data shown for different cancer types (adapted from Verhoeven et al. 1997b)
Number of studies showing an association for one or
more brassica vegetables (of which statistically
significant)
Cancer site Inverse association Positive association Total number of studies
Colon 11 (6) 4 (0) 15
Stomach 8 (5) 3 (1) 11
Rectum 8 (4) 3 (0) 10
Lung 9 (6) 2 (0) 9
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In summary, indications for the chemopreventive potential
of cruciferous vegetables, glucosinolates and their break-
down products in in vitro studies and studies with experimen-
tal animals are quite strong. These data support the results of
many epidemiological studies showing beneficial effects of
cruciferous vegetables. In contrast, human data on particular
chemical entities in these vegetables (their actual exposure as
well as their effects) are scarce.
10.3. Polycyclic aromatic hydrocarbons (PAHs)
Polycyclic aromatic hydrocarbons (PAHs) always exist as
mixtures in the environment, and are present in smoke,
char-grilled food, exhaust gases from engines and from
several industrial processes. Workers from industrial set-
tings with high airborne PAH-levels such as gas works,
coke works and primary aluminium industries show excess
rates of lung cancer. More than seven PAHs are known to be
carcinogenic (Mumtaz et al. 1996).
PAHs are present in food due to environmental pollution
or from heat processing. Most leafy vegetables take up
PAHs from the air, especially when the vegetables are
grown in the neighbourhood of emission sources. Uptake
of PAHs by plants can also occur from the soil. Certain sea-
foods, such as mussels and oysters, can contain high levels
of PAHs, and char-grilling, grilling and smoking of meat
and fish increases the PAH level. Daily intake is estimated
to be 3–16mg/day (de Vos et al. 1990).
Although more than 100 different PAHs are known,
extensive knowledge is only available on the metabolism
of just one of the carcinogenic PAHs, benzo(a)pyrene.
The intermediate epoxide-benzo(a)pyrene and benzo(a)pyr-
ene diol epoxide covalently bind to nucleophilic sites in
DNA to form benzo(a)pyrene-DNA adducts. These type
of metabolites are carcinogenic intermediates of benzo(a)-
pyrene and, in general, of the PAH.
A biomarker of exposure measures either the internal
dose in body fluids or measures the dose at the target site
in an exposed individual. Since PAHs are a group of com-
pounds, two approaches can be followed. The biomarker
can be a marker of the whole group, or a marker specific
for a single compound. A large variety of approaches and
techniques have been tested, e.g. PAH levels in blood and
urine, reduction of PAH levels in urine, urinary thioethers,
mutagenicity in urine and DNA–PAH adducts in white
blood cells, using a wide range of different techniques
such as methods involving bacteria, UV- and fluorescence
spectrometry, immunochemical methods, GC-MS and
liquid chromatographic methods. The composition of indi-
vidual PAHs in different diets varies, and so when a single
compound is used as an indicator or marker, this is not
necessarily a good indicator of total intake. Thus there is a
need to have a good overall biomarker of effect representing
the changing PAH-content, especially of the carcinogenic
representatives (Table 7).
10.4. Heterocyclic amines (HAs)
Proteins in cooked meat can be the source of many sub-
stances with mutagenic or carcinogenic potential. Reaction
products between amino acids and sugars give rise to Mail-
lard reaction products that contribute to taste and flavour,
but at prolonged very high temperatures give rise to more
toxic substances. The food-derived heterocyclic aromatic
amines (HAs) comprise a group of about 20 compounds
that have been isolated from cooked animal protein (meat
and fish) and from the pyrolysis of proteins and individual
amino acids. HAs have been recognised as potent mutagens
in the Salmonella-microsome assay (Ames-test) and as car-
cinogens in long-term rodent experiments. Circumstantial
evidence suggests that these compounds are also likely to
elicit carcinogenesis in humans (Sugimura, 1997, for
review).
The types and levels of HAs in foods are dependent
on multiple factors such as type of meat (beef, chicken,
fish), cooking techniques and temperature, degree of
cooking and browning of the surface. The HAs from
dietary sources which are most relevant to human health
are: IQ, 2-amino-3-methylimidazo(4,5-f(quinoline)); MeIQ,
2-amino-3,4-dimethylimidazo(4,5-f(quinoline)); MeIQx, 2-
amino-3,8-dimethylimidazo(4,5-f(quinoxaline)); and PhIP,
2-amino-1-methyl-6-phenylimidazo(4,5-b(pyridine)).
Table 6. Non-nutritive chemopreventive substances: sources and possible mechanisms of action (adapted from Verhagen et al. 1997b)
Possible mechanism(s)*
Chemo-preventive agents Primary sources 1 2 3 4 5 6 7 8
Carotenoids Fruits, vegetables, cereal x x x
Chlorophyllin Leafy vegetables x x x
Coumarins Vegetables, citrus fruits x x
Diallyl sulphides Onion, garlic x
Dietary fibre Fruits, vegetables, legumes, seeds x
Flavonoids Fruits, vegetables, tea x x x x x x
Indoles Cruciferous vegetables x x x x
Terpenoids Citrus fruits x x
Isothiocyanates Cruciferous vegetables x x
Phenolic acids Fruits, vegetables, nuts, tea, coffee. x x x x x x x x
Phytic acid Legumes, cereals x x
Plant sterols Vegetables x x x
Protease inhibitors Seeds, legumes, grains x x
* Mechanism(s): 1, Prevention of formation/uptake of carcinogens; 2, scavenging of (activated) carcinogens; 3, shielding of nucleophilic sites in DNA; 4, inhibition
of formation of DNA/carcinogen complex; 5, modifying the activities of biotransformation enzymes; 6, modifying the activities of other enzymes; 7, antioxidant
activity; 8, other.
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HAs require metabolic activation, in particular N-hydroxy-
lation of exocyclic amino groups, by CYP1A2, and sub-
sequent esterification of the N-hydroxylamine, to form the
ultimate highly reactive ester derivatives. The genotoxic
N-hydroxy metabolites or their N-sulphate and N-acetoxy
esters can react with electrophilic sites in protein and
DNA. Individual differences in metabolic constitution
such as levels of cytochrome P450 and N-acetyltransferase
will influence individual susceptibility towards these com-
pounds. Genotoxic activity results in various precarcino-
genic effects such as mutations in oncogenes and tumour
suppressor genes (H-ras, p53, apc ), sister-chromatid
exchanges and chromosomal aberrations. In addition to
measuring levels of HAs in the human diet, there are
other methods to measure human exposure to these com-
pounds: protein adducts, DNA-adducts and urinary
metabolites.
Measurement of adducts to proteins such as haemoglobin
and serum albumin have the advantage of abundance, long
life and ease of accessibility, but the data for HA protein
adducts are very limited, even for in vitro and animal studies
(Turesky & Markovic, 1995). Only a handful of studies are
available for DNA adducts with several HAs (particularly at
the C8 position of guanine) in animals and humans (Turesky
& Markovic, 1995; Schut et al. 1997; Nerurker et al. 1996).
Parent compounds, their metabolites (conjugates with glu-
curonic acid, sulphate, and glutathione) and DNA-adducts
(upon excision repair) have been reported to be excreted
in the urine of animals and humans, but again the data are
very limited (Ji et al. 1994; Turesky & Markovic, 1995;
Singh & Rothman, 1997; Snyderwine et al. 1997).
In summary, HAs are well recognised as relevant dietary
risk factors for humans. Their potential as mutagens and car-
cinogens is established, and the bioactivation mechanism
underlying their genotoxic potential is understood. In con-
trast, only few data are available to monitor exposure to
these compounds. Animal data on metabolism are limited
and there are even less human data. Future research should
focus on the monitoring of reactive metabolites (protein-
and DNA-adducts) and urinary excretion products.
10.5. Other non-nutrients
The subject area of food additives is vast and includes both
natural and synthetic substances covering a large range
of chemical entities, all of which must be subjected to
extensive toxicity testing prior to approval. It is a heavily
regulated area and good biomarkers of exposure and effect
would enable realistic risk assessment and achievable regu-
lations to be set. This is vital for EU and world trade con-
siderations. Generally, animal studies in vivo are used to
confirm that the food additive does not exhibit any undue
toxic effects and to set a level of exposure, the acceptable
daily intake which is associated with negligible risk for
human consumption. EU Member States are required to
establish additive consumption monitoring surveys (EC,
1994a,b, 1995). Biomarkers offer the means by which
more direct, accurate and relevant (i.e. human health-
related) data on food additive intake may be obtained com-
plementary to established procedures such as per capita
estimates, total diet studies and chemical analysis, thereby
allowing better assessment of the risks associated with
intake (Tennant, 1995).
Some examples illustrating the advantages and difficul-
ties of biomarker measurements for food additives are
given below.
10.5.1. Deliberately added compounds
Saccharin and acesulfame-K. The artificial sweeteners
saccharin and acesulfame-K can be consumed at high levels,
especially by children, diabetics and slimmers (ca. 35–50 %
of the acceptable daily intake). Both compounds are
excreted in the urine unmetabolised. Suitable methods of
analysis have been developed as a means of estimating
intake (Wilson and Crews, 1995, Wilson et al. 1999). The
data showed good general agreement between calculated
and measured intakes with urinary measurements providing
additional information on exposure to sources not revealed
by the questionnaire approach, e.g. drugs, toothpaste. This
type of anomaly can be countered by good questionnaire
design.
Azo dyes. Consumption of some of the azo dyes used as
artificial food colorants has been linked to allergenic
response, notably hyperactivity in children. Both the parent
compounds and the products of metabolic microbial or
hepatic azo-reduction (i.e. sulphonated aromatic amines)
have been found in urine and faeces, and are promising can-
didates for biomarkers of exposure. Although most data are
from animal studies (Jones et al. 1964; Phillips et al.
1987a–c; Chung et al. 1992b; Singh et al. 1993), some
human studies are attempting to establish exposure/excre-
tion relationships, which is complicated by the occurrence
of metabolites common to several azo dyes thus limiting
Table 7. Characteristics of available biomarkers of exposure to PAH (from
Jongeneelen, 1997)
Parent agent Biomarker
Total PAH as a mixture Aromatic PAH-adducts in white blood cells
Total PAH as a mixture Urinary thioethers
Total PAH as a mixture Mutagenicity in urine
Specific PAH PAH in urine after reduction
Specific PAH Hydroxylated PAH
Benzo(a)pyrene Adduct DNA-benzo(a)pyrene in white blood cells
Benzo(a)pyrene Adduct haemoglobin-benzo(a)pyrene
Benzo(a)pyrene 3-Hydroxy-benzo(a)pyrene
Phenanthrene Hydroxyphenanthrenes in urine
Pyrene 1-Hydroxypyrene in urine
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biomarker specificity. In addition, little or none of the parent
compound may be found at detectable levels in urine
(Wilson and Crews, personal communication, 1999)
Hydrocarbon fractions from refined mineral oils and
waxes. Various animal studies have shown that specific
fractions of hydrocarbon material from refined mineral
oils and waxes are preferentially absorbed and transported
intact to tissues with the major portion excreted in the
faeces. Bioaccumulation is affected by the physicochemical
properties of the hydrocarbons concerned (molecular
weight, viscosity, steric factors) and has been associated
with increased organ weights (e.g. liver, kidney).
Microscopy has revealed the presence of liver granulomas
and other clinical changes have been observed such as
lesions on the cardiac mitral valve (Baldwin et al. 1992; Fir-
riolo et al. 1995; Miller et al. 1996; Nash et al. 1996; Smith
et al. 1996). However, such obvious markers of exposure
and effect are not suitable for human studies because of
the necessary invasiveness required for sample collection.
Hence, better biomarkers need to be identified (i.e. urinary,
faecal, plasma) so that the links between dietary exposure,
accumulation and excretion can be established. Only limited
animal and human data are available on metabolic products
of relatively short-chain hydrocarbons (Fedtke & Bolt,
1987a,b).
Butylated hydroxyanisole (BHA) and butylated hydroxy-
toluene (BHT). The synthetic phenolic compounds buty-
lated hydroxyanisole and butylated hydroxytoluene have
widespread use as lipophilic antioxidants. Some individuals
show allergic reactions to butylated hydroxyanisole and it is
carcinogenic in the forestomach of rodents (Verhagen et al.
1990a). It is a strong inducer of oxidative DNA damage in
the epithelial cells of the glandular stomach in rats (Schil-
derman et al. 1995a) and has been implicated in the in vitro
induction of oxidative DNA damage and enhancement of
cell proliferation in human lymphocytes (Schilderman
et al. 1995b) monitored by increased levels of the biomarker
8-oxodG. Conjugated urinary metabolites of butylated
hydroxyanisole (i.e. sulphates, glucuronides) have been
identified as biomarkers of exposure. Low levels may be
determined but methods have yet to be validated (Verhagen
et al. 1989, 1990a,b, 1991a,b). Butylated hydroxytoluene is
known to inhibit tumour formation by several chemical car-
cinogens, including aflatoxin B1, by induction of hepatic
glutathione-S-transferases (Allameh, 1997). However, the
links between dietary exposure of butylated hydroxyanisole
and butylated hydroxytoluene and health are not relevant at
dose levels below the respective acceptable daily intakes.
Although many other food additives have been of recent
toxicological interest, valid biomarkers have yet to be ident-
ified, e.g. the intense sweeteners aspartame and cyclamate,
caffeine, gallate ester antioxidants, the flavour enhancer
monosodium glutamate, sulphites, nitrate and nitrite preserva-
tives, the dough improver potassium bromate, carbohydrate
polyesters, starch hydrolysates and smoke condensates.
10.5.2. Contaminants and processing artifacts. This is a
vast area hence only a few examples are discussed.
Phthalates and related compounds. Di-2-ethylhexyl
phthalate (DEHP), a peroxisome proliferator, has proved
to be a non-genotoxic carcinogen in rodent studies. The
toxicology of other phthalates is less well investigated.
Phthalates also demonstrate oestrogenic activity and have
been associated with polycystic ovaries and testicular atro-
phy in experimental animals (Medical Research Council,
1995). DEHP is reported to have no effect on sulphotrans-
ferase expression (Witzmann et al. 1996). The metabolism
of phthalate esters has been studied widely (Thomas &
Northup, 1982; Egestad & Sjoberg, 1992). The parent die-
ster phthalate is not excreted in the urine but is rapidly de-
esterified to form the corresponding phthalate monoester, a
proportion of which is further metabolised. There are very
few detailed metabolic studies on phthalate esters in humans
and those that are available focus on di-2-ethylhexyl phtha-
late. In general between 10 and 50 % of an administered
dose is recovered in the urine within 24 hours as metab-
olites. The fate of di-2-ethylhexyl phthalate following oral
ingestion of 30 mg has been examined and it was shown that
the monoester derivative accounted for about 10 % of the
total metabolites excreted in the urine in 24 hours (Schmid
& Schlatter, 1985). In a similar study, a somewhat higher
figure of 20 % has been reported (Albro et al. 1982). In a
reported case of occupational exposure, mostly airborne,
the monoester derivative accounted for 26 % of total metab-
olites (Dirven et al. 1993). Gas chromatography–mass
spectrometry (GC-MS) has been used to analyse alkylated
monoesters following extraction from urine (after deconju-
gation with b-glucuronidase) using solvent partition and
solid-phase clean-up. HPLC with UV detection has also
been used to analyse phthalate monoesters but is not as sen-
sitive as GC-MS. The mass spectrometric characterisation
and quantitation of both diester- and monoesterphthalates
have been reported using electron impact (Dirven et al.
1993) and chemical ionisation (Muszkat et al. 1997). Thermo-
spray HPLC-MS has similarly been used (Baker, 1996).
These data strongly suggest that the monoester derivatives
of diester phthalates are likely to be promising candidates
as urinary biomarkers of exposure. However, the available
data only relate to 2-di-ethylhexyl phthalate and have been
generated using either extreme exposure levels or airborne,
rather than oral, administration. As a consequence they
cannot be utilised to quantitatively relate urinary levels
of the metabolite to dietary exposure of the parent phtha-
lates. Before such a biomarker-based approach is adopted,
the relationship between dietary exposure and urinary
excretion needs to be established. Urinary metabolite
measurements have been used to confirm estimated daily
intakes of di-2-(ethylhexyl), adipate a plasticiser found in
PVC-based food wrapping materials (Massey, 1995).
BADGE. Bisphenol A diglycidyl ether (BADGE) and its
hydrolysis products, such as bisphenol-A, possess oestro-
genic activity (Sumpter & Jobling, 1995). The oestrogen
receptor-binding affinities have been examined (Waller
et al. 1996). There are significant gaps in the knowledge
especially with regard to vitellogenesis. The quality and
quantity of biological data for relevant biomarkers of tox-
icity and hormonal responsiveness are limited and bio-
markers are needed. Susceptible (genetic) risk groups may
include low age groups and males
Nitrosamines. The class of nitrosamines consists of
many compounds (volatile and non-volatile). The different
nitrosamines are implicated in various health diseases
(Wishnok et al. 1993; Lockwood et al. 1994; Monarca
Biomarkers linked with dietary intake S25
et al. 1996) and all are known to produce carcinogenic
tumours (lung cancer, stomach cancer, colon cancer). Bio-
markers of exposure include urinary biomarkers, increased
cytosine DNA-methyltransferase activity and DNA modifi-
cations. For certain nitrosamines such as those occurring in
tobacco smoke, biomarkers have been characterised (Chang
et al. 1994; Falter et al. 1994; Kresty et al. 1996; Hecht,
1996b; Pirier & Weston, 1996). The usefulness of the var-
ious candidate biomarkers is complicated by the multiplicity
of nitrosamine compounds present in a wide variety of food-
stuffs. High consumption of foods containing nitrite and/or
nitrate may possibly increase exposure to nitrosamines and
susceptibility to disease.
Chloropropanols. Chloropropanols are formed from
protein hydrolysates which are used widely as seasonings
and savoury flavours, by the reaction of hydrochloric acid
with residual lipids. In a study of chronic effects in F344
rats, high doses of 3-monochloro-1,2-propanediol
(3-MCPD) produced benign renal tumours in both sexes
and Leydig-cell and mammary tumours in males.
3-MCPD is genotoxic in vitro, but there is no evidence of
genotoxicity in vivo. The non-genotoxic mechanisms
associated with rat studies and the lack of carcinogenicity
of 3-MCPD in mice and Sprague–Dawley rats, have been
concluded to have developed as a result of non-genotoxic
mechanisms and are considered not to be relevant to humans
exposed to trace amounts of 3-MCPD (Lynch et al. 1998).
Very low levels have been found in foods and food ingredi-
ents, formed possibly as a result of processing or storage.
Theoretically, small amounts of 3-MCPD could pass from
some food contact materials (e.g. epichlorohydrin resins)
into food. Currently there are no biomarkers for exposure
to 3-MCPD in humans.
Xylenes. Xylenes (o-, m- and p-) are widely used in
industry and medical technology as solvents. In addition,
several food components are known to degrade during pro-
cessing to produce these and similar compounds. For ex-
ample, at relatively high (.708C) temperatures,
carotenoids can undergo a series of degradation reactions
to produce a range of products including aromatic com-
pounds, principally xylene and toluene. The main aromatic
thermal degradation product of the apocarotenoid colouring
component of annatto (E160b) has been identified as
m-xylene (McKeown, 1963, 1965; Scotter, 1995). m-Xylene
has been found in commercial annatto food-colouring prep-
arations up to a level of 200 mg/kg (Scotter et al. 2000) and
has been detected in the headspace of heated foodstuffs con-
taining annatto (Scotter, unpublished results). Recently, the
amount of the major metabolite of xylene, methylhippuric
acid, in urine has been recommended as an indicator of
exposure. Of the xylene absorbed, about 95 % is metab-
olised in the liver to methylhippuric acid and 70–80 % of
metabolites are excreted in the urine within 24 hours. No
studies have been made on chronic exposure to xylene(s)
from dietary sources. Animal studies have failed to provide
convincing evidence that xylene is carcinogenic or has sig-
nificant genetic or reproductive effects but they have con-
firmed that xylene has effects on many organ systems,
including the CNS, liver, kidney, haemopoietic tissues and
respiratory tract (Langman, 1994). Metabolites of xylene(s)
in untreated urine have been readily characterised and
measured by HPLC (Tamburini et al. 1995; Moon et al.
1997). These data strongly suggest that isomers of methyl-
hippuric acid are likely to be promising candidates as urin-
ary biomarkers of exposure to xylenes. However, the
available data have only been generated using either
extreme exposure levels or airborne, rather than oral, admin-
istration. As a consequence they cannot be utilised as they
stand to quantitatively relate urinary levels of the metabolite
to dietary exposure of xylenes. Before such a biomarker-
based approach is adopted, the relationship between dietary
exposure and urinary excretion needs to be established.
11. Conclusions
Biomarkers have been defined as indicators of actual or
possible changes of systemic, organ, tissue, cellular and sub-
cellular structural and functional integrity which can be
used, either singly or in batteries, to monitor health and
exposure to compounds in populations and individuals
(Koletzko et al. 1998). In the preceding sections we have
given many examples of the complexities involved in
using some biomarkers in relation to assessing the effects
of dietary exposure, from understanding why the biomarker
might be valuable and how best it can be measured, to the
pitfalls which can occur in the interpretation of data. The
two other reviews in this issue of the British Journal of
Nutrition discuss the use of biomarkers in epidemiological
studies (Wild et al. ) and the role of biomarkers in disease
and health with special reference to cancer, coronary heart
disease and osteoporosis (Hanley et al. ).
Many of the difficulties cited in all three reviews arise
from the need to determine changes following long-term
low-level exposure, or absence of exposure, to dietary com-
ponents. Intake measurements based on food analysis and
dietary intake tables have been proven to be a useful first
step but their value is limited by their accuracy. Solving
some of these difficulties would involve, ideally, long-
term studies of human subjects and their diets but the
resources required for such undertakings are frequently pro-
hibitively expensive. The aim for biomarker research in
health and disease should be the application of biomarkers
to the development of preventive interventions for use in
human populations. Disease due to factors other than essen-
tial nutrient deficiency is unlikely to be radically improved
by dietary intervention alone. However, overall health and
well-being can be improved by dietary intervention alone
but this goal requires considerable advances in the under-
standing of the functions of dietary components and further
improvements in the analytical techniques to measure and
study these processes.
Importantly, it also requires the political will to facilitate
the dissemination of information about appropriate diets and
to make them readily available worldwide. This review was
carried out as part of a European project and the authors
acknowledge the support given by the EC.
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